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Abstract
The present study assessed whether the atypical antipsychotic agents olanzapine,
risperidone, and quetiapine are associated with significant weight gain among adults with
intellectual disabilities after 6 months of drug treatment. The body weights of 79
participants were retrieved 6 months prior to the initiation of drug treatment, at the start
of the atypical antipsychotic agent, and after 6 months of drug therapy. Each individual
served as his or her own control by utilizing pretreatment baseline trends in weight
change to calculate a dependent measure of adjusted posttreatment weight gain. Doing so
allowed for a stringent determination of the liability for weight gain during drug
treatment. Results indicated that olanzapine, risperidone, and quetiapine are each
associated with significant weight gain after 6 months of drug treatment. Individuals with
mild to moderate intellectual disabilities evidenced more significant weight gain within
that time period than those with severe to profound impairments.
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Weight Gain among Adults with Intellectual Disabilities
Receiving Atypical Ant psychotics
For thirty years and as recently as a few years ago, the simple fact of being mentally
retarded and residing in an institution meant that one was treated, like it or not, with
neuroleptic drugs. The doses were high, the treatment went on for years, and little or
no consideration was given to side effects that the drugs would have [emphasis
added], (Gualtieri, 1991, p. 36)
Few issues are more controversial in the field of intellectual disabilities (ID) than
the use and potential misuse of psychotropic medication. Landmark epidemiological
research published in 1970 found that 51.1% of persons with ID residing in institutional
settings were receiving psychotropic medication (Lipman, 1970). More than 39% were
being chronically treated with "major tranquilizers", agents now typically referred to as
neuroleptic or antipsychotic drugs. Subsequent investigation revealed that adults with ID
comprised the most medicated of all treatment groups in inpatient psychiatric wards
(Aman, 1987).
More recent investigations continue to confirm that a substantial percentage of
persons with ID are prescribed psychotropic drugs. A 1988 review of the published
literature estimated that between 40% to 50% of those in institutional settings and 25% to
35% of those in community settings were being prescribed psychotropic medication
(Aman & Singh, 1988). Research from 1997 subsequently revealed that 36.5% of persons
with ID enrolled in Oklahoma's state healthcare system were receiving at least one
psychotropic agent (Spreat, Conroy, & Jones, 1997). The majority of individuals, 22.4%,
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were being treated with antipsychotic drugs. The remaining 14.1% were receiving
antidepressant, anxiolytic, or anticonvulsant agents for mood or behavioral stabilization.
A 2004 extension of this state healthcare research revealed no significant change
in psychotropic prevalence rates, with 34.3% of persons with ID continuing to receive at
least one psychotropic drug (Spreat, Conroy, & Fullerton, 2004). Antipsychotic agents
remained the most widely prescribed psychotropic medication, with an estimated 20.0%
of adults receiving this class of drug. The highest prescription rates for antipsychotic
drugs occurred among adults with ID living in nursing homes at 31.7%. Prescription rates
for antipsychotic drugs were somewhat lower and almost identical for those residing in
supported independent living settings and institutional facilities, at 19.6% and
19.5%, respectively.
Antipsychotic drugs generally are separated into two broad categories: the
conventional or first-generation agents and the more recently developed atypical or
second-generation agents (Baldessarini & Tazari, 2006). Chlorpromazine, also known by
the trade name Thorazine, was the first conventional antipsychotic introduced to the U.S.
market. The advent of chlorpromazine in 1954 constituted a landmark event for the field
of psychopharmacology, and this drug continues to be recognized for revolutionizing the
rehabilitation of persons with schizophrenia. Utilization of chlorpromazine from 1954 to
1980 decreased the population of psychiatric inpatients by more than 400,000 in the
United States. Furthermore, this drug set the stage and the marker for the development of
other agents to treat severe clinical disorders.
Numerous research trials and years of clinical experience have established that
antipsychotic drugs are superior to psychological therapies, benzodiazepines,
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barbiturates, and electroconvulsive shock in treating the cardinal signs and symptoms of
schizophrenia and other disorders marked by psychosis (Baldessarini & Tarazi, 2006).
Antipsychotic drugs are recognized to be highly effective in minimizing delusions,
hallucinations, combativeness, psychomotor agitation, insomnia, negativism, and
anorexia. More variable or delayed responses also are noted with some aspects of
cognition, motivation, and self-care. For instance, improvements often are seen in
orientation, judgment, insight, and memory during the course of antipsychotic
drug treatment.
As a result of their therapeutic efficacy, the Food and Drug Administration (FDA)
have approved antipsychotic drugs for a range of disorders (Baldessarini & Tazari, 2006).
Common indications include (a) acute and chronic psychotic disorders (e.g.,
schizophrenia, delusional disorder, brief psychotic disorder, acute idiopathic psychosis,
and alcoholic hallucinosis); (b) mood disorders with psychotic features
(e.g., bipolar mania and severe depression); (c) cognitive disorders marked by
psychomotor agitation or aggression (e.g., delirium and some types of dementia);
(d) self-injurious behavior (SIB) associated with ID and pervasive developmental
disorders (PDDs) (e.g., autism); (e) Gilles de la Tourette syndrome; (f) Huntington's
disease; and (g) nausea and emetism.
Since the introduction of chlorpromazine in 1954, antipsychotic drugs have
remained the most frequently prescribed class of psychotropic drug for adults with ID
(Aman, 1987; Aman & Singh, 1988; Lipman, 1970; Spreat et al., 1997; Spreat et al.,
2004). These agents are used to treat comorbid clinical disorders and, more
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controversially, to manage a variety of aberrant behaviors in the absence of an Axis I
diagnosis (Ashcroft, Fraser, Kerr, & Ahmed, 2001; Deb, Sohanpal, Soni, Lenotre,
& Unwin, 2007; Janowsky, Barnhill, Khalid, & Davis, 2006; Levitas, 2003; McGillivray
& McCabe, 2004; Unwin & Deb, 2008). Clinical disorders are believed to be three to
four times more prevalent among adults with ID than in the general population
(American Psychiatric Association [APA], 2002), with estimates ranging from 9% to
74% across various disorders (American Association on Mental Retardation [AAMR],
2002). However, diagnostic overshadowing, or the tendency for clinicians to attribute
sustained disturbances in mood and behavior to ID rather than to a co morbid clinical
condition, is believed to contribute to an underdiagnosis of psychotic and mood disorders
among adults with ID (Dosen & Day, 2001).
Many persons with ID display behavioral disturbances that are severe and chronic
but difficult to classify as a clinical disorder using the criteria set forth in the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR,
APA, 2002) or the International Classification of Disease, Tenth Edition (World Health
Organization [WHO], 1992). For instance, many individuals with ID have cognitive and
communication deficits that make it challenging for clinicians to reliably identify
disturbances of thought and perception (Aman, Crimson, Frances, King, & Rojahn, 2004;
Cooper, Melville, & Einfeld, 2003; Dossetor, 2007; Rush, Bowman, Eidman, Toole, &
Mortenson, 2004; Rush & Frances, 2000). This diagnostic uncertainty only increases with
the severity of ID (Aman et al.; Rush & Frances).
Although the identification of clinical disorders remains ideal in guiding treatment
efforts, "Expert Consensus Guidelines" recognize that, other than autism, any diagnosis is
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difficult to reliably formulate in persons who function within the severe to profound
range of ID (Aman et al., 2004; Rush & Frances, 2000). Thus, observable disturbances in
behavior, such as sustained psychomotor agitation, SIB, physical aggression, and
property destruction, often become the foci of antipsychotic drug treatment. Because such
behavioral signs are not primary diagnostic features of specific clinical disorders, and
instead may reflect the current effects of multiple psychosocial and biomedical
conditions, they typically are considered nonspecific in nature. Some research supports
the use of antipsychotic drugs to treat behavioral disturbances commonly associated with
ID, autism, and other PDDs (Aman & Gharabawi, 2004; Cohen, Ihrig, Lott, & Kerrick,
1999; Kahn, 1999; McAdam, Zarcone, Hellings, Napolitano, & Schroeder, 2002;
Zarcone, Hellings, Crandall, Reese, Marquis, Fleming, et al., 2000). This practice
remains controversial, however, and is viewed by many as a failure to appropriately
formulate and treat the underlying etiology of the behavioral disorder (Ashcroft et al.,
2001; Deb et al., 2007; Janowsky et al., 2006; La Malfa, Lassi, Bertelli, & Castellani,
2006; Levitas, 2003; Luchins, Dojka, & Hanrahan, 1998; Matson, Bamburg, Mayville,
Pinkston, Bielecki, Logan, et al., 2000; Matson, Bielecki, Mayville, & Matson, 2003;
McGillivray & McCabe, 2004).
The effectiveness of antipsychotic drug treatment for adults with ID and
comorbid clinical disorders is similar to the morbid psychiatric population, although the
amount of research published is smaller by comparison (Aman et al., 2004; Duggan &
Brylewski, 1999; La Malfa et al., 2006; Shedlack, Hennen, Magee, & Cheron, 2005).
Consistent with clinical practice, much of the available research has investigated the
effectiveness of antipsychotic drugs in managing behavioral disturbances among persons
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with ID (Aman et al.; Aman & Gharabawi, 2004; Ashcroft et al., 2001; Deb et al., 2007;
Dinca, Paul, & Spencer, 2005; Hammock, Levine, & Schroeder, 2001; Horrigan &
Barnhill, 1999; Janowsky et al., 2006; Kahn, 1999; McAdam et al., 2002; McGillivray &
McCabe, 2004; Williams, Clarke, Bouras, Martin, & Hoult, 2000; Zarcone et al., 2000).
The International Consensus Handbook presents a comprehensive research review of the
efficacy and effectiveness of different antipsychotic drugs in treating behavioral
disturbances commonly evidenced by persons with ID (Baumeister, Sevin, & King 1998).
Other than aggression, for which results were mixed, clinical improvements were noted
with all aberrant behaviors for the majority of individuals.
The conventional or first-generation antipsychotic drugs, however, do not always
effectively treat severe behavioral disturbances evidenced by persons with ID,
particularly among those also diagnosed with autism (Baumeister et al., 1998).
Furthermore, concerns abound that the low-potency or high-dose conventional
antipsychotics largely achieve clinical results by exerting nonspecific effects on a broad
range of behaviors. These agents have the potential to cause significant sedation and
thereby may suppress aberrant behaviors as well as adaptive performance, cognition, and
learning. Consequently, skills training and other habilitative efforts may be made more
difficult for persons who are already at pervasive disadvantage. Conversely, the
high-potency or low-dose conventional antipsychotics frequently cause neurological
damage marked by debilitating and potentially irreversible disturbances in motor activity
(Baldessarini & Tazari, 2006).
The life expectancy of persons with ID has dramatically increased over the past
60 years (Chaney & Eyman, 2002; Hogg, Juhlberg, & Lambe, 2007). The frequency and
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severity of adverse drug reactions, however, remain significantly higher for the ID
population than the general public (Wilson, Lott, & Tsai, 1998). Considering that
behavioral and clinical disorders often emerge in childhood and extend throughout
adulthood in persons with ID, and that there has been a 50-year trend of antipsychotic
drugs being the most widely prescribed psychotropic for these individuals, the issue of
antipsychotic drug treatment remains highly charged (Aman & Singh, 1988; Lipman,
1970; Spreat et al., 1997; Spreat et al., 2004).
Pathophysiology of Psychosis: Increased Dopaminergic Activity
To understand the therapeutic and adverse effects of antipsychotic drugs, both the
conventional and atypical agents, an overview of their mechanisms of action is necessary.
In the brain, dopamine functions as a neurotransmitter and neurohormone that activates
five types of receptors—Dl, D2, D3, D4, and D5 (Baldessarini & Tazari, 2006).
Dopamine is released by naturally reinforcing experiences such as food and sex and is
commonly associated with the pleasure system (Berridge & Robinson 2001; Bratcher,
Farmer-Dougan, Dougan, Heidenreich, & Garris, 2005). Dopamine has various other
functions, however, and also plays an important role in (a) mood (Ruhe, Mason, &
Schene, 2007); (b) motor activity (Andersson, Nissbrandt, & Bergquist, 2006;
Soiza-Reilly, Fossati, Ibarra, & Azcurra, 2004); (c) wakefulness and sleep (Monti &
Jantos, 2008); (d) attention and cognition (Saeedi, Remington, & Christensen, 2006;
Savitz, Solms, & Ramesar, 2006; Silkstrom & Soderlund 2007); (e) learning and memory
(Cheng & Feenstra, 2006; El-Ghundi, O'Dowd, & George, 2007; Frank & O'Reilly,
2006; Olvera-Cortez, Anquiano-Rodriguez, Lopez-Vazquez, & Alfaro, 2008); and
(f) regulation of milk production (Tabak, Toporikova, Freeman, & Bertram, 2007).
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Dopaminergic neurons project throughout various structures of the brain
(Baldessarini & Tazari, 2006; Kapur, Mizrahi, & Li, 2005; Miyamoto, Duncan, Marx, &
Lieberman, 2005). The highest concentrations are found within four major neural tracts
that include the mesolimbic, mesocortical, nigrostriatal, and tuberinfundibular pathways.
The pathophysiology of idiopathic psychoses results from increased dopaminergic
activity in the mesolimbic and mesocortical regions of the brain. The mesolimbic
pathway is associated with arousal, latent inhibition, goal direction, pleasure, and reward.
Overactivity of dopamine in this region is linked with the positive symptoms of
psychosis, most notably delusions and hallucinations. The mesocortical pathway is
associated with motivated behavior, emotional response, and several neurocognitive
functions including memory, attention, and problem solving. Overactivity of dopamine in
this region is linked with the negative symptoms of psychosis, such as affective blunting,
avolition, and alogia.
To ameliorate the positive and negative symptoms of psychosis, dopaminergic
overactivity must be dampened in the mesolimbic and mesocortical brain regions
(Baldessarini & Tazari, 2006; Miyamoto et al., 2005). The limbic and cortical systems
are connected via parallel circuitry that penetrates the nigrostriatal region of the brain.
The nigrostriatal pathway, which forms part of the complex motor loop of the basal
ganglia, regulates movement and motor control through the activity of dopaminergic
neurons. Degeneration of dopaminergic neurons along the nigrostriatal tract is a major
pathological feature of Parkinson's disease and other extrapyramidal disorders.
In addition to the mesocortical, mesolimbic, and nigrostriatal pathways,
dopaminergic neurons are also highly concentrated in the tuberinfundibular region of the
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brain (Baldessarini & Tazari, 2006; Miyamoto et al., 2005). This region houses the
pituitary gland and assists in regulating the secretion of certain hormones such as
prolactin. Dopamine serves to inhibit the release of prolactin in the tuberoinfundibular
region, and in its absence milk is continuously secreted (Baldessarini & Tazari;
Miyamoto et al.; Tabak et al., 2007).
Although the precise mechanisms of action underlying antipsychotic drugs remain
unclear, receptor binding patterns provide clues about their efficacy, tolerability, and
safety (Baldessarini & Tazari, 2006; Miyamoto et al., 2005). The affinity of a drug, or the
degree to which it binds to a particular receptor site, predicts both drug potency and the
likelihood for side effects. Common to all antipsychotic drugs, both the conventional and
the atypical agents, is their affinity to antagonize or block the dopamine receptor subtype
D2 in the limbic and prefrontal regions of the cerebral cortex. What differentiates these
agents are the method and specificity by which this antagonism occurs.
Conventional Antipsychotic Drugs
A brief history. Conventional antipsychotic drugs are commonly referred to as
"neuroleptics", a term derived from the Greek wherein "neuro" refers to nerves and
"lept" means "to seize or take hold" (Baldessarini & Tazari, 2006). Thus, the word
neuroleptic literally means "to seize or take hold of nerves". Conventional antipsychotic
drugs originally were called neuroleptics to contrast their effects against barbiturates and
other sedative-hyponotics which depress the functioning of the central nervous system
(CNS). Although conventional antipsychotic drugs reduce spontaneous motor
movements, complex behaviors, and emotional responsiveness, they do not significantly
depress other CNS functions respiration, heart rate, spinal reflexes, or unconditioned

avoidance responses. As a result, neuroleptic drugs primarily were regarded as more
viable sedative agents, for which they also became known as "tranquilizers" or "major
tranquilizers" until their antipsychotic and antimanic properties were well established.
Today, the term "tranquilizer" has fallen into general disfavor for conventional
antipsychotic drugs because this label falsely implies an association with the
benzodiazepines or minor tranquilizers.
The term neuroleptic became increasingly popular after conventional
antipsychotic drugs were put to broad use in the chronic treatment of psychosis and their
liability to cause movement disorders became apparent (Baldessarini & Tazari, 2006).
Historically, the emergence of motor disturbances was considered an important clinical
indicator that the drug dose was sufficient to treat psychosis. Such views remained
largely intact until the 1980s ushered in significant advances in neurophysiologic
research. Conventional antipsychotic drugs were then increasingly recognized as having
an impact on many neurotransmitter sites throughout the nervous system, resulting in
therapeutic as well as unwanted effects. Disturbances in motor control eventually were
understood to be a reliable measure of drug-induced neurological damage rather than a
valid index of therapeutic dosing. Today, the term neuroleptic generally is used to
reference the neurological disturbances that are strongly associated with the
conventional, but not the atypical, antipsychotic drugs.
Pharmacokinetics and pharmacodynamics. Conventional antipsychotics can
be divided into eight categories that include 25 different drugs (Baldessarini & Tazari,
2006). Although all are efficacious in treating psychosis, particularly the positive
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symptoms, results are achieved at the significant risk for neurological side effects that
can be grossly impairing and irreversible (Baldessarini & Tazari; Miyamoto et al., 2005).
Knowledge of the mechanisms that underlie both the antipsychotic and neurological
effects of conventional antipsychotic drugs remains incomplete. However, their strong
affinity to antagonize dopamine in the limbic portions of the forebrain and the basal
ganglia are the most prominently discussed.
Conventional antipsychotics are strong antagonists for D2 receptors in the
mesolimbic pathway, and to a lesser extent in the mesocortical pathway, and thereby
effectively minimize symptoms of psychosis (Baldessarini & Tazari, 2006; Miyamoto et
al., 2005). Because the parallel circuitry of the limbic and cortical systems extends
throughout the nigrostriatal brain region, conventional antipsychotics also inactivate the
dopaminergic neurons that control involuntary motor movements. Antagonism of D2
receptors in the nigrostriatal system results in an elevated risk for adverse neurological
effects, particularly acute extrapyramidal symptoms upon initiation of the drug and
tardive dyskinesia upon the discontinuation of chronic drug treatment or, in more severe
cases, while the agent is still being administered.
Extrapyramidal symptoms. Meaningful motor movements, reflexes, balance,
and posture are all controlled via the contractions of voluntary and involuntary skeletal
muscle (Baldessarini & Tazari, 2006). Two motor tracts in the brain control skeletal
muscle, the pyramidal and the extrapyramidal systems. The pyramidal system produces
voluntary actions whereas the extrapyramidal system controls involuntary movements.
Voluntary motor movements are initiated in the brain by the primary motor cortex
whose neurons have long axons that tighten together as they travel down the spinal cord
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(Baldessarini & Tazari, 2006). Motor commands travel down these v-shaped neural
tracts, collectively known as the "pyramidal system", until they synapse with the motor
neurons that control skeletal muscle. The pyramidal system thus produces voluntary
motor movements through direct innervation of the brain stem and spinal cord.
Neural feedback loops infiltrate the nigrostriatal pathway and basal ganglia to
modulate the activity of the motor neurons in the pyramidal system (Baldessarini &
Tazari, 2006). These neural feedback loops are housed outside the pyramidal tract and do
not directly inneverate the motor neurons of the brain stem and spinal cord.
Collectively referred to as the "extrapyramidal system", these neural loops control
involuntary motor movements, posture, and muscle tone. The extrapyramidal system
serves as a necessary compliment to the pyramidal system by inhibiting involuntary
motor movements and thereby promoting the initiation of voluntary actions.
Dysfunction of the extrapyramidal system produces involuntary motor
movements and suppresses the ability to initiate voluntary movements (Baldessarini &
Tazari, 2006). Any set of conditions in which the quality or quantity of motor movements
become abnormal due to dysfunction of this system are referred as extrapyramidal
symptoms (EPS). Conventional antipsychotic drugs have prominent extrapyramidal
effects due to antagonism of dopamingeric neurons in the nigrostriatal pathway, a major
component of the basal ganglia's complex motor loop (Baldessarini & Tazari; Miyamoto
et al., 2005).
Common EPS include (a) akathisia, or restlessness, pacing, and insomnia;
(a) dystonia, or repetitive muscular spasms that typically affect the eyes, neck jaw, and
tongue; (b) bradykinesia, or decreased voluntary motor movements and abnormalities of

posture and muscle tone (c) akinesia, or an inability to initiate voluntarily movements;
(d) drug-induced parkinsonism, or tremors, shuffling gait, muscle stiffness, and rigidity;
and (e) tardive dyskinesia, or repetitive, nonrhythmic tics and slow writhing movements
of the face, extremities, and trunk (Baldessarini & Tazari, 2006).
An estimated 50% to 75% of individuals treated with conventional antipsychotic
drugs develop EPS, with figures exceeding 90% for some high-risk groups (Baldessarini
& Tazari, 2006). EPS are recognized as the leading cause of medication noncompliance
among persons treated with conventional agents (Linden, Scheel, & Eich, 2006).
Approximately 50% of schizophrenic outpatients and 40% of day hospital patients are
thought to be noncompliant with their medication regimen due to EPS. Furthermore, EPS
due to conventional antipsychotic drug treatment increases the likelihood for cognitive
impairment and neuroleptic dysphoria (Baldessarini & Tazari; Tenback, van Harten,
Slooff, van Os, & SOS Study Group, 2006). Anticholingeric drugs such as benzotropine
(Cogentin) and trixyphenidly (Artane) remain the standard treatments for EPS but carry
the potential to further impair learning, cognition, and memory (Chew, Mulsant, &
Pollock, 2005).
Tardive dyskinesia. As highlighted by Sadock and Sadock (2005), conventional
antipsychotic drugs "have effects that can be distressing even to highly motivated
patients, let alone those who are fearful and mistrustful. An important consideration in
drug selection must be the avoidance of the most uncomfortable or dangerous adverse
reaction—tardive dyskinesia [emphasis added]" (p. 242).
The term "tardive dyskinesia" (TD) was coined in 1964 to describe the tics and
associated motor disturbances that patients are now recognized to be at high risk for
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developing when chronically exposed to or withdrawn from conventional antipsychotic
drugs (Baldessarini & Tazari, 2006). "Tardive" refers the delayed onset of the motor
abnormalities that arise with chronic or maintenance drug treatment. The literature
variably defines chronic drug exposure as 3 to 12 months of medication receipt, not an
unusual time course given that antipsychotic agents are a primary treatment for disorders
marked by delusions and hallucinations, grossly disorganized and agitated behaviors, and
repeated aggressive and self-injurious acts. A potentially irreversible neurological
disorder, TD often persists after—and actually can be exacerbated by—the discontinuation
of conventional antipsychotic drug treatment.
TD is characterized by a variety of involuntary hyperkinetic movements,
choreoathetoid movements, and speech difficulties (Baldessarini & Tazari, 2006).
Hyperkinetic movements often affect the orofacial region and include quick, nonrhythmic
ticks of tongue, jaw, brow, and facial muscles as well as repetitive lip smacking and oral
chewing. Choreoathetoid movements are characterized by slow, writhing movements of
the digits, hands, feet, limbs and abdomen and may resemble the squirming of a snake.
Speech difficulties typically result from enlargement and protrusion of the tongue due to
overdevelopment of the tongue muscles from involuntary motor movements. Severe TD
affects the entire body and closely resembles Huntington's chorea.
The etiology of TD is a neural phenomenon known as "upregulation" (Marchan &
Dilda, 2006; Miyamoto et al., 2005). In response to prolonged blockade of dopaminergic
receptors, postsynaptic neural membranes in the nigrostriatal region and throughout the
basal ganglia develop a compensatory supersensitivity to dopamine by generating
additional receptors that are highly responsive to this neurotransmitter. The dopamine-

mediated neural networks that serve motor control consequently have the potential to
become easily overstimulated. Upregulation frequently results in TD when a
conventional antipsychotic drug is titrated downward or withdrawn. Among chronically
treated and high-risk groups, upregulation may become so pronounced that it
overcompensate for the drug and causes TD while the agent is still being administered at
a maintenance dose.
Approximately 30% of persons treated with conventional antipsychotic drugs
develop TD (APA, 2002). Numerous factors are recognized to increase the risk for this
adverse drug reaction. For example, within the morbid psychiatric population, the
prevalence of neuroleptic-induced TD is approximately 5% for young adults but exceeds
50% for middle-aged and elderly adults (APA).
Factors that have been associated with an increased risk for the development of
neuroleptic-induced TD include (a) higher doses of the conventional agent, (b) longer
durations of drug treatment, (c) increasing age, (d) psychosis predominantly marked by
negative symptoms, and (e) cognitive deficits manifested by learning disabilities and ID
(Wszloa, Newell, & Sprague, 2001). A strong positive association has been noted
between the degree of neuropsychological impairment and the severity and course of TD
(Paulsen, Heaton, & Jeste, 1994; Wonodi, Hong, & Thaker, 2005). Individuals treated
with conventional antipsychotic drugs are more likely to develop severe and unremitting
TD if they evidence preexisting impairments in (a) attention and information processing,
(b) learning and memory, (c) visuoperceptual skills, (d) verbal abstraction, and (e) global
cognitive functioning (Paulsen et al.).
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Understanding the role of conventional antipsychotic drugs as they relate to motor
disturbances in persons with ID remains a complex issue. The prevalence of various
neuromuscular disorders, including idiopathic or neuroleptic naive dyskinesia, is
significantly higher in the ID population than both the general public and morbid
psychiatric groups (Paulsen et al., 1994; Wonodi et al., 2005). Exposure to conventional
antipsychotic drugs dramatically raises the already heightened risk for extrapyramidal
disturbances and dyskinetic disorders in persons with ID.
Approximately 75% of persons with ID develop withdrawal TD during the
titration or shortly after the discontinuation of conventional antipsychotic drug treatment
(Paulsen et al., 1994). Unremitting TD remains in at least 30% these individuals.
Reliable identification of neuroleptic-induced movement disorders requires systematic
monitoring of persons with ID because self-stimulatory behaviors, stereotypies, tics,
muscular dystonias, and degenerative palsies can all mask the presence of TD from even
the most observant clinician. As noted by Shedlack et al., (2005), "[t]he presence of any
movement disorder or mannerism in these patients makes diagnosis, observation over
time, and treatment of the motor condition a puzzle" (p. 57).
Atypical Antipsychotic Drugs
A brief history. In an effort to broaden the therapeutic efficacy and reduce the
side effect profile of conventional antipsychotic drugs, the development of new
medications began being pursued in the 1980s (Baldessarini & Tazari, 2006).
The discovery that specific receptor subtypes are preferentially concentrated in the
different brain pathways, and thereby can be selectively or even partially inhibited,
allowed for the development of drugs with high antipsychotic efficacy and minimal
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liability for extrapyramidal effects. These agents are commonly referred to as the secondgeneration or atypical antipsychotic drugs, so named due to their substantially reduced
risk for adverse neurological effects. Clozapine, also known by the trade name Clozaril,
was the first atypical antipsychotic introduced to the U.S. market. The advent of
clozapine in 1990 marked the most significant advance in the psychopharmacology of
antipsychotic drugs since the introduction of chlorpromazine 46 years earlier.
Clozapine remains the only drug to receive FDA approval for treatment-resistant
schizophrenia and reducing the risk of suicidal behaviors in persons with psychotic
disorders (Hennen & Baldessarini, 2004). If not for the side effect of agranulocytosis, an
acute and potentially lethal suppression of bone marrow for which the FDA restricts
clozapine to third-line use and mandates regular blood analyses, this drug would certainly
be considered first line of treatment. Nonetheless, clozapine has served as the model for
the development of all other atypical antipsychotic drugs.
Since the marketing of clozapine in 1990, five atypical antipsychotic drugs have
received approval by the FDA for use the in United States: (a) risperidone (Risperdal) in
1993, (b) olanzapine (Zyprexa) in 1996, (c) quetiapine (Seroquel) in 1997,
(d) ziprasidone (Geodon) in 2001, and (e) aripiprazole (Abilify) in 2002 (Baldessarini &
Tazari, 2006). All five agents are approved as first lines of treatment for schizophrenia
and acute mania associated with bipolar disorder (AstraZeneca Pharmaceuticals, 2007;
Bristol-Myers Squibb, 2007; Eli Lilly, 2007; Janssen Pharmaceutics 2007; Pfizer, 2007).
Several atypical drugs also carry approved indications for (a) depressive and mixed
episodes of bipolar disorder, (b) prophylaxis of bipolar disorder, (c) major depressive
disorder, and (d) irritability associated with autism. Atypical antipsychotic drugs are also

frequently prescribed for several off-label indications that have received support through
clinical research, including (a) acute psychosis associated with alcohol intoxication and
psychostimulant use; (b) degenerative psychosis associated with Parkinson's disease;
(c) tic disorders; (d) trichotillomania; (e) behavioral disturbances associated with
personality disorders; and (f) behavioral disorders associated with ID and PDDs
(Baldessarini & Tazari, 2006).
Improved clinical outcomes and reduced liability for neurological side
effects. Atypical antipsychotic drugs hold several distinct advantages over their
conventional predecessors. Placebo-controlled trials, comparative research, and
meta-analytic reviews indicate that the atypical antipsychotics have equivalent or
improved efficacy and effectiveness in the treatment of positive psychotic symptoms
among the morbid psychiatric population (Davis, Chen, & Glick, 2003; Meltzer,
Arvanitis, Bauer, & Rein, 2004; Meyer, 2007; Turner & Stewart, 2006; Vohora, 2007;
Wang, Savafe, Borisove, Rosenberg, Woolvine, Tucker, et al., 2006) and persons with
comorbid ID and PDDs (Aman & Garabawai, 2004; Aman & Madrid, 1999; Hammock et
al., 2001; Shedlack et al., 2005). Atypical antipsychotic drugs also are more effective in
treating negative psychotic symptoms and cognitive dysfunction and may thereby reduce
social withdrawal (Hori, Noguchi, Hashimoto, Nakabayashi, Omori, Takahashi, et al.,
2006; Shedlack et al.). Such effects may be particularly significant for the treatment of
persons with ID. As noted by Shedlack et al., "social withdrawal is often a constitutional
feature of mental retardation and can easily go unrecognized as a treatable complex of
negative symptoms. Isolation and introversion may be mistaken for meekness or lacking
sophistication rather than preoccupation due to psychosis" (p. 61).
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Atypical antipsychotics show markedly improved effectiveness over conventional
agents in the treatment of behavioral disorders among persons with ID (Aman &
Gharabawi, 2004; Aman & Madrid, 1999; Deb et al., 2007). These drugs more effectively
reduce stereotypies, compulsions, SIB, and physical aggression. Furthermore, the atypical
antipsychotics demonstrate success with otherwise refractory cases among morbid
psychiatric patients (Davis et al., 2003; Dunner, 2005; Meltzer, 2004) and persons with
psychiatric or behaviors disorders and comorbid ID, particularly those diagnosed with
autism (Aman & Gharabawi; Aman & Madrid; Deb et al.; Hammock et al., 2001;
Horrigan & Barnhill, 2001).
The atypical antipsychotic drugs evidence a significantly reduced liability for EPS
and TD among the morbid psychiatric population and high risk groups, most notably
geriatric adults and persons with ID (Advokat, Mayville, & Matson, 2000; Dunner, 2005;
Harpreet & Mendhekar, 2006; Leucht et al., 1999; Meltzer, 2004; Nasrallah, 2006; Tarsy
& Baldessarini, 2006). The reduced anticholinergic properties of these drugs also make
them less likely to suppress cognition, learning, and adaptive behaviors than the
conventional antipsychotic agents (Hori et al., 2006; Shedlack et al., 2005). As a result of
their broader therapeutic efficacy and more favorable side-effect profile, medication
compliance is approximately 30% higher with the atypical agents than their conventional
predecessors (Linden et al., 2006).
Pharmacokinetics and pharmacodynamics. Atypical antipsychotic drugs are
able to achieve therapeutic integrity while minimizing many of the adverse effects
associated with the conventional antipsychotics by binding more selectively at specific
brain regions (Baldessarini & Tazari, 2006). Although the precise mechanisms of action

for this class of drugs remain uncertain and are believed to differ somewhat from agent to
agent, the therapeutic efficacy of the atypical antipsychotics is known to derive from
more specific modulation of dopamine. All atypical antipsychotics display a reduced
affinity for D2 receptors in the nigrostriatal pathway and basal ganglia and therefore are
not significantly associated with extrapyramidal effects (Baldessarini & Tazari;
Miyamoto et al., 2005). Nonetheless, these drugs achieve potent antidopaminergic
activity in select brain regions though their strong affinity to antagonize one or more
serotonin or 5-hydoxytryptamine (5-HT) receptor subtypes—particularly 5-HTia, 2a, 2c, 3,
and 6~as well as the norepinephrine receptor subtypes a\ and «2 (Baldessarini & Tazari;
Meltzer & Huang, 2008; Miyamoto et al.; Richtand, Welge, Logue, Keck, Strakowski, &
McNamara, 2008; Stone, Davis, Leucht, & Pilowsky, 2008).
Antagonism of 5-HT produces regional antagonism of D2 receptors in the
mesolimbic and mesocortical regions of the brain but minimally impacts D2 receptors in
the nigrostriatal region (Baldessarini & Tazari, 2006; Meltzer & Huang, 2008; Miyamoto
et al, 2005; Richtand et al., 2008; Stone et al., 2008). Consequently, atypical
antipsychotic drugs preferentially impact the D2 receptors responsible for positive and
negative psychotic symptoms over those that control involuntary motor movements,
thereby mitigating the probability and severity of EPS and TD. Furthermore, the
additional effects on 5-HT receptors, possibly in concert with antagonism of the
a2-adrenergic receptors located on these neurons, are believed to contribute to the
amelioration of negative psychotic symptoms and associated cognitive dysfunction.
Although all atypical antipsychotics selectively impact D2 receptors in the
mesolimbic and mesocortical pathways via antagonism of 5-HT, their affinity for any

particular 5-HT receptor subtype differs by agent (Baldessarini & Tazari, 2006;
Miyamoto et al., 2005; Richtand et al., 2008). As a result, each atypical antipsychotic
displays relatively unique pharmacologic characteristics in relation to (a) gender
(Aichhorn, Gasser, Weiss, Adlassnig, & Marksteiner, 2005; McEvoy, Meyer, Goff,
Nasrallah, Davis, Sullivan, et al., 2005); (b) gene expression (Bakker, van Harten, & van
Os, 2006; Hill & Reynolds, 2007); (c) mode of action (Meltzer & Huang, 2008;
Miyamoto et al.; Richtand et al.; Stone et al., 2008); (d) efficacy (Davis et al., 2003;
Meltzer, 2004; Meltzer et al., 2004; Meltzer & Huang; Richtand et al.; Stone et al.); and
(e) side effect profile (de Leon & Diaz, 2007; Meltzer; Meltzer et al.; Meltzer & Huang;
Meyer, Davis, Goff, McEvoy, Nasrallah, Davis, et al., 2008; Stone et al.; Wilson,
D'Souza, Sarkar, Newton, & Hammond, 2003). The atypical antipsychotics are more or
less associated with various adverse drug reactions that may include sexual side effects,
hypotension, electrocardiographic changes, weight gain, hyperlipidemia, diabetes
mellitus (DM) type II, and diabetic ketoacidosis (Baldessarini & Tazari). Weight gain and
the associated potential for DM type II with atypical antipsychotic drug treatment has
generated the most concern, although the research to date suggests the liability for these
side effects substantially differs by agent (de Leon & Diaz; Meltzer et al.; Meyer et al.;
Wilson et al.).
The Obesity Epidemic and Associated Health Consequences
The last several decades have witnessed epidemic increases in overweight and
obesity among the general population (Baskin, Ard, Franklin, & Allison, 2005; Centers
for Disease Control & Prevention [CDC], 2008; Parikh, Pencina, Wang, Lanier, Fox,
D'Agostino, et al., 2007). Overweight and obesity, respectively defined as body mass
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index (BMI) scores equal to or greater than 25 kg/m and 30 kg/m , are currently
considered the most rapidly increasing and difficult to treat medical conditions
worldwide (Caballero, 2007; Potter, 2006; Prentice, 2006; Yach, Stuckler, & Brownell,
2006). As noted by Prentice,
[t]he obesity pandemic originated in the US and crossed to Europe and the
world's other rich nations before, remarkably, it penetrated even the world's
poorest countries especially in their urban areas [where] projected numbers of
new cases of diabetes run into the hundreds of millions within the next 2 decades,
(p. 93)
The World Health Organization has used BMI as the standard for recording
obesity statistics since the early 1980's (National Institutes of Health, 1998). In 1998, the
National Institutes of Health aligned the U.S. definitions of overweight and obesity to
correspond with best practice guidelines of the World Health Organization. As a result,
approximately 30 million Americans previously considered normal weight came to be
defined as clinically overweight or obese. By the year 2000, approximately 35% of men
and 33% of women were considered overweight in the United States (Parikh, 2007);
an additional 20% of men and 18% of women met criteria for obesity. From 2000 to
2004, trends for overweight remained stable for American adults (Parikh; Ogden, 2006).
Obesity, however, increased by 11% for men and 15% for women to total 31% and 33%
of the population, respectively (Ogden). Over the past decade, this steady rise in weight
has earned the United States first place for obesity statistics among the developed world.
A causal relationship between weight gain and psychological or physical
dysfunction is difficult to establish as other factors such as sedentary lifestyle may play a
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role in etiology. Nonetheless, an overwhelming amount of research confidently attributes
overweight and obesity to a variety of adverse consequences. Individuals who are
overweight or obese, for example, have heightened perceptions of discrimination and
indeed are more susceptible to social stigmatization than persons who are normal weight
(Ashmore, Friedman, Reichmann, & Musante, 2008; Carr & Friedman, 2005). Many of
these individuals score significantly lower on measures of self-esteem, psychological
well-being, and psychosocial adjustment (Blaine, Rodman, & Newman, 2007; Carr &
Friedman; De Hert, Peuskens, Van Winkel, Kalnicka, Hanssens, Van Eyck, et al., 2006;
Provencher, Polivy, Wintre, Pratt, Pancer, Birnie-Lefcovitch, et al., 2008). Increased rates
of negative affect, depression, anxiety, and binge eating are also noted among persons
who are overweight or clinically obese (Ashmore et al.; Carr, Friedman, & Jaffe, 2007;
Provencher et al.).
Overweight and obesity also are strongly associated with compromised
functioning across multiple body systems including the endocrine, genitourinary,
gastrointestinal, musculoskeletal, renal, pulmonary, cardiovascular, and neurological
systems (Akinnusi, Pineda, & El Solh, 2008; Bray & Bellanger, 2006; Popkin Kim,
Rusev, Du, & Zizza, 2006). In order of direct cost of treatment, overweight and obesity
are most strongly associated with the following medical conditions: (a) DM type II;
(b) coronary artery disease; (c) osteoarthritis; (d) hypertension; (e) gallbladder disease;
and ( f ) cancer of the colon, breast, endometrium, and prostate (Popkin et al.).
Overweight and obesity are also established risk factors for numerous other medical
conditions including hypoventilation, sleep apnea, asthma, gallstones, thromboembolism,
atherosclerosis, impaired glucose tolerance, hypertriglyceridemia, hypercholesterolemia,
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cardiovascular disease, and stroke (Akinnusi et al.; Bray & Bellanger; Popkin et al.).
Furthermore, overweight and obesity are linked to increased mortality from various
disease states, with estimates ranging from 20% to 40% for middle-aged adults and 20%
to 55% for geriatric adults (Adams, Schatzkin, Harris, Kipnis, Mouw, Ballard-Barbash, et
al., 2006; Greenberg, Fontaine, & Allison, 2007; Janssen & Bacon, 2008). Mortality rates
may be higher for particular diseases, such as with cardiovascular mortality which
increases by approximately 50% for middle-aged adults who are clinically obese (Adams
et al.).
Obesity is a well-established risk factor for "metabolic syndrome" or the
development of a constellation of diseases that include (a) hypertension or elevated blood
pressure, (b) dyslipidemia or high triglycerides and low high-density lipoprotein
cholesterol; and (c) impaired fasting glucose (Bray & Bellanger, 2006; Despres, 2006;
Lois, Young, & Kumar, 2008). These metabolic disturbances often cluster together and
heavily predispose individuals for atherosclerosis, cardiovascular disease, and DM type
II. Obesity is additionally recognized to be an independent causative factor for the
development of DM type II, the more common form of diabetes that accounts for 95% of
all cases in the United States (Bindler, 2007; Gagliari & Wittert, 2007). As summarized
by Bindler, "[ijnsulin resistance and metabolic syndrome are direct outcomes of
increasing obesity rates, which, in turn, lead to the emergence of type II diabetes" (p. 29).
Obesity is believed to directly contribute to DM type II because adipose or fatty
tissue is the primary source of the hormones and cytokines that serve as chemical signals
to increase insulin resistance (Aguilera, Gil-Campose, & Gil, 2008; Mobbs, Isoda,
Makimura, Mastaitis, Mizumo, Shu, et al., 2005). Individuals who are over 20% their

ideal body weight are at heightened risk of DM type II (CDC, 2005). As of 2002, slightly
more than 30% of American adults were diagnosed with DM type II. Over 85% of these
individuals weighed significantly more than their recommended weight range.
Approximately 30% met clinical criteria for overweight, and an additional 56% crossed
the threshold for obesity (CDC, 2005). Consequently, researchers such as Gagliari and
Wittert (2007) have emphasized "management of obesity as the primary strategy [italics
added] for management of disorders of glucose metabolism" (p. 95)
Overweight and Obesity in Persons with Schizophrenia
An estimated 2.4 million Americans suffer from schizophrenia (Wu, Shi,
Birnbaum, Hudson, Kressler, 2006). For nearly a decade, these individuals have been
recognized to be at significantly greater risk for overweight and obesity than the general
population (Allison, Fontaine, Heo, Mentore, Cappelleri, Changer, et al., 1999; Leas &
McCabe, 2007; McEvoy et al., 2005). Indeed, recent estimates suggest that 60% to 63%
of adults with schizophrenia meet criteria for obesity (Barnett, Mackin, Chaudhry,
Farooqi, Gadsby, Heald, et al., 2007; Kolotkin, Corey-Lisle, Crosby, Swanson, Tuomari,
L'italien, et al., 2008).
Overweight and obesity among persons with schizophrenia have been linked to
diminished outcomes in several key areas: (a) medication compliance (Perkins, 2002);
(b) clinical outcomes (Kurzthaler & Fleischhacker, 2001); (c) self-esteem (De Hert,
Peuskens, et al., 2006); (d) quality of life (Kolotkin, Corey-Lisle, et al., 2008; Kolotkin,
Crosby, Corey-Lisle, Li, & Swanson, 2006); (e) physical health (Barnett et al., 2007;
Kolotkin, Corey-Lisle, et al.; Leas & McCabe, 2007; Miller, Paschall, & Svendsen,
2006); and (f) mortality (Barnett et al.; Miller et al.). Obesity-related medical conditions
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such as heart disease and DM type II largely account for the increased mortality rate of
persons with schizophrenia which averages 30 years earlier than the general population
(Miller et al.). For instance, the increased prevalence of overweight and obesity among
persons with schizophrenia increases cardiovascular mortality by 300% over that of the
general population.
Various explanations have been proposed to account for the increased prevalence
of overweight and obesity among persons with schizophrenia. Low physical activity,
inappropriate and excessive food intake, socioeconomic status, antipsychotic drug
treatment, and the psychiatric disorder itself have all been discussed as possible
contributing factors (Jean-Baptiste, Tek, Liskov, Chakunta, Nicholls, Hassan, et al., 2007;
Khazaal, Fresard, Zimmerman, Trombert, Pomini, Grasset, et al., 2006; Leas & McCabe,
2007; Strassnig, Brar, & Ganguli, 2005; Strassnig, Miewald, Keshavan, & Ganguli, 2007;
Weber, 2008). In late 2003, the FDA revised the product label requirements for atypical
antipsychotic drugs due to media reports and the public's increasing concerns that weight
gain may be a class effect of treatment with this class of medication (Burton, 2003;
Goode, 2003; Rosack, 2003). Shortly afterward, statements regarding the increased
liability for weight gain and DM type II began to be included in the package inserts of all
atypical antipsychotics (AstraZeneca, 2008; Bristol-Myers Squibb, 2008; Eli Lilly, 2008;
Janssen, 2008; Novartis, 2008; Pfizer, 2008).
The rising concern of weight gain with atypical antipsychotic drug treatment.
The FDA Modernization Act of 1997 streamlined the process for drug approval to three
phases which are completed in 10 to 12 months (Oates, 2006). As Oates has detailed, this
expedited approval process "can only detect the most profound and overt risks that occur

almost immediately after a drug is given" (p. 133). Although risk assessment is one
component of phase three drug trials, the revamped FDA approval process is nonetheless
primarily suited to answering questions about drug efficacy. Phase three trials are
generally limited to 2,000 to 3,000 carefully selected participants, with only a few
hundred receiving drug treatment for more than 3 months, regardless of the anticipated
duration of clinical treatment. Consequently, many unanticipated therapeutic and adverse
effects are not detected until a drug had come into broad use on the market. As Oates
has cautioned:
Because of limitations in the capacity of the premarketing phase of drug
development to define delayed or uncommon but significant risks of new drugs,
postmarketing surveillance of drug usage is imperative to detect such adverse
effects. Some patients, because of unique genetic or environmental factors, are at
an extremely high risk, whereas the remainder of the population may be at low or
no risk. (p. 133)
In late 2004, concerns about the growing body of postmarket research linking
atypical antipsychotic drugs to weight gain and DM type II prompted the American
Psychiatric Association, American Diabetes Association (ADA), American Association
of Clinical Endocrinologists (AACE), and North American Association for the Study of
Obesity (NAASO) to convene a consensus development conference to further investigate
this issue. This panel concluded that the liability for weight gain varies considerably
across atypical antipsychotic drugs and ranges from minimal to significant (APA, ADA,
AACE, & NAASO, 2004). Clozapine and olanzapine were judged to have the greatest
effects on weight. Risperidone and quetiapine were believed to have intermediate effects,

although the amount of weight gain with these agents was still often significant.
Comparative data for ziprasidone was limited but suggested that this drug has little to no
effect on weight. Sufficient data was not available on aripiprazole to make any initial
determination of its liability for weight gain. Although studies on aripiprazole remain
minimal at this time, limited research suggests that weight gain with this drug is also
negligible (De Hert, Hanssens, van Winkel, Wampers, van Eyck, Scheen, et al., 2007;
Kim, Ivanova, Abbasi, Lamendola, Reaven, & Glick, 2007).
Weight gain with atypical antipsychotic drug treatment implicated in
metabolic syndrome. Atypical antipsychotics continue to be associated with adverse
drug reactions unrelated to the neuromuscular system and not typically seen with the
conventional agents. Research has increasingly linked atypical antipsychotic drug
treatment to the triad of metabolic disturbances collectively known as metabolic
syndrome: (a) weight gain and obesity, (b) hyperlipidemia, and (c) glucose dysregulation
and DM type II (Baldessarini & Tazari, 2006; Barnes, Paton, Cavanagh, Hancock, &
Taylor, 2007; De Hert, Schreurs, Van Eyck, Hanssens, Wampers, Scheen, et al., 2008;
de Leon & Diaz, 2007; McKee, Bodfish, Mahorney, Heath, & Ball, 2005; Meltzer, 2004).
Indeed, the risk for metabolic syndrome with atypical antipsychotic drug treatment is of
such potential significance that it has been called "the tardive dyskinesia" of the
second-generation agents (McKee et al., p. 1164). Among the triad of metabolic
disturbances associated with the atypical antipsychotics, weight gain represents a
particular concern because it is an established causative factor in the dysregulation of
both lipid and glucose levels (International Diabetes Federation, 2005).
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Although controlled clinical studies remain limited at this time, numerous case
reports, retrospective investigations, and epidemiological studies indicate that the risk for
weight gain and associated metabolic disturbances is greater with some atypical
antipsychotic drugs than others. Moderate to severe metabolic reactions are most
frequently implicated with the dibenzodiazepine-derived compounds which include
clozapine, olanzapine, and risperidone (Baldessarini & Tazari, 2006; De Hert et al., 2008;
McKee et al., 2005; Meltzer, 2004). The majority of research conducted to date focuses
on weight gain with olanzapine and risperidone because these two agents are FDA
approved as first lines of treatment for schizophrenia and bipolar mania and both
demonstrate a strong potential to produce a domino effect of metabolic dysregulation.
Pharmacokinetics and pharmacodynamics. Although the pathophysiology
remains obscure, weight gain with atypical antipsychotic drug treatment is believed to be
related to changes in histaminergic and monoamine signaling. The atypical antipsychotics
most strongly associated with weight gain demonstrate a strong affinity for histamine Hi
and serotonin 5- HT2C receptors and a moderate affinity for adrenergic ocia and 0,2
receptors (Baldessarini & Tazari, 2006; De Luca, Mueller, de Bartolmeis, & Kennedy,
2007; Matsui-Sakata, Obtani, & Sawada, 2005; Reynolds, Hill, & Kirk, 2006).
Clozapine and olanzapine, which have a high risk for weight gain, show a strong affinity
for Hj and 5-HT2C receptors which affect hunger, satiety, and adipocyte function
(Baldessarini & Tazari; Matsui-Sakata et al.). Aripiprazole and ziprasidone, which have a
low risk for weight gain, demonstrate minimal affinity for these receptors.
Weight gain due to atypical antipsychotic treatment is believed to be directly
responsible for the increased risk of hyperlipidemia among patients receiving these drugs

(Meyer, 2001a; Meyer, 2001b). Hyperlipidemia is a primary culprit for peripheral
vascular disease, atherosclerosis, coronary artery disease, and ischemic cerebrovascular
disease (Mahley & Bersot, 2006). These conditions account for the majority of morbidity
and mortality among middle-aged and older adults. Drug-induced hyperlipidemia and
consequent medical diseases represent a particular concern for persons with ID because
this population already evidences a significantly higher cardiovascular risk than the
general population (Beange, McElduff, & Baker, 1999).
Although most literature on the risk for DM type II with atypical antipsychotic
drug treatment involves case reports or open label studies with small sample sizes (for an
overview, see de Leon & Diaz, 2007; Miller, Leslie, & Rosenheck, 2005), limited
research using larger sample sizes has been published (Basu & Meltzer, 2006; Miller et
al.). Preliminary results implicate that both weight gain and elevated serum prolocatin
occurring with atypical antipsychotic drug treatment increase the risk for glucose
dysregulation and new-onset DM type II (de Leon & Diaz; Miller et al.). This increased
risk for DM type II translates into additional direct medical costs exceeding $800 million
annually within the US (Basu & Meltzer). Furthermore, diabetes is associated with
impairments in processing speed and visual-spatial ability, and the comorbid occurrence
of DM type II with mental illness has been related to additional declines in these brain
functions as well as to significant deterioration in general cognitive and community
functioning (Dickinson, Gold, Dickerson, Medoff, & Dixon, 2008).
New-onset DM type II is generally asymptomatic, and one half of all cases are
estimated to remain undiagnosed (Barnes et al., 2007). Consequently, the risk for this
disease with atypical antipsychotic drug treatment is likely underappreciated. In an effort
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to promote early detection and intervention, diabetes screening programs are being
increasingly emphasized as an essential component of treatment monitoring for those
receiving atypical antipsychotic drugs (Basu & Meltzer, 2006).
A Closer Look at the Atypical Antipsychotics: Approved Uses, Mechanisms of
Action, and Liability for Weight Gain
Clozapine. The first atypical antipsychotic drug to be developed, clozapine, is
currently approved by the FDA for treatment-resistant schizophrenia and reducing the
risk of recurrent suicidal behavior in schizophrenia and schizoaffective disorder (Hennen
& Baldessarini, 2004; Novartis, 2008). Clozapine's profile of binding to dopaminergic
and serotoninergic receptors classifies it as an atypical antipsychotic (Baldessarini &
Tazari, 2006; Miyamoto et al., 2005). Clozapine differs from the conventional agents in
that it shows a strong affinity for D4 and 5HTia receptors and is preferentially more
active in the mesolimbic than the nigrostriatal pathway. Consequently, this drug is highly
effective in treating both the positive and negative symptoms of schizophrenia while
evidencing a negligible risk for EPS and TD. Clozapine is also a strong antagonist at
adrenergic, cholinergic, and histaminergic receptors, with the last two predominantly
accounting for its side effect profile.
Clozapine is the most efficacious drug for schizophrenia but is restricted to
third line of treatment due to the risk for several potentially fatal side effects:
(a) agranulocytosis, or acute suppression of white blood cells; (b) myocarditis, or acute
inflammation of the heart muscle; and (c) cardiomyopathy, or chronic deterioration of the
heart muscle (Novartis, 2008). Because of such risks, the FDA requires clozapine to carry
five black box warnings, and patients prescribed this drug are required to undergo weekly

blood monitoring through what is commonly known as a "No Blood, No Drug" policy
(Baldessarini & Tazari, p. 495; Novartis). In addition to the risk for agranulocytosis and
cardiac toxicity, clozapine is also frequently associated with weight gain, hyperglycemia,
and new-onset DM type II (Novartis).
Weight gain is a common side effect of clozapine treatment, occurring in more
than 30% of persons who received this drug for at least 6 weeks in open-label studies and
randomized, placebo-controlled clinical trials (Covell, Weissman, & Essock, 2004;
Novartis, 2008). Clozapine also is associated with the greatest weight gain relative to
other atypical antipsychotics (ADA et al., 2004; Allison & Casey, 2001).
Meta-analysis of 81 studies which utilized 30,000 measures of weight among psychiatric
patients without comorbid ID who were treated with atypical antipsychotic drugs
identified a mean weight increase of 9.18 lb (4.16 kg) after 10 weeks of clozapine
treatment (Allison & Casey). Weight gain has been shown to drastically increase by 6
months of clozapine treatment, with a mean increase of 16.50 lb (7.48 kg) noted in one
retrospective analysis (Wirshing, Wirshing, Kysar, Berisford, Goldstein, Pashdag, et al.,
1999). Weight gain is believed to contribute to the increased risk of new-onset DM type
II among patients receiving clozapine (ADA et al.; Novartis), for which incidence rates
range from 12.8% to 43% per recent epidemiological research (Cohen, Stolk, Grobbee, &
Gispen-de Wied, 2006; Henderson, Nguyen, Copeland, Hayden, Borba, Louie, et al.,
2005; Lamberti, Costea, Olson, Frilly, Maharaj, Tu, et al., 2005).
Olanzapine. Olanzapine is the most frequently prescribed atypical antipsychotic,
with an estimated 20 million people receiving treatment worldwide and $4.2 billion
generated annually in drug sales (Berenson, 2007). Olanzapine is currently approved by
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the FDA for (a) schizophrenia, (b) acute manic episodes, (c) depressive episodes
associated with bipolar disorder, and (d) maintenance treatment of bipolar disorder
(Eli Lilly, 2008). Common off-label uses include the treatment of Tourette syndrome and
anorexia nervosa and adjunctive treatment of major depressive disorder without psychotic
features (Baldessarini & Tazari, 2006). Case reports and open-label study also suggest
that olanzapine may be an effective augmentative treatment for refractory generalized
anxiety disorder and panic disorders (Hollifield, Thompson, Ruiz, Uhlenhuth, 2005;
Pollack, Simon, Salta, Worthington, Hoge, Mick, et al., 2006).
Olanzapine is classified as an atypical antipsychotic due to its high affinity for
several 5-HT receptor subtypes which, in concert with regional antagonism of D2
receptors, accounts for the therapeutic effects of this drug (Baldessarini & Tazari, 2006;
Miyamoto et al., 2005). Antagonism of 5-HT2C receptors and Hi receptors are implicated
in olanzapine's frequent and severe liability for weight gain; these receptors are thought
to affect hunger and satiety as well as promote fat deposition through direct effects on
adipocyte function.
Weight gain is a common side effect of olanzapine treatment, occurring in over
75% of persons who received this drug for 4 to 6 weeks in open-label studies and
randomized, placebo-controlled clinical trials (Bobes, Rejas, Garcia-Garcia,
Rico-Villadernoros, Garcia-Portilla, Fernandez, et al., 2003; Eli Lilly, 2008).
The magnitude of weight gain with olanzapine is only slightly less than clozapine and the
most severe among the atypical antipsychotic drugs approved as first lines of treatment
(ADA et al., 2004; Allison & Casey, 2001). Meta-analysis of over 80 studies on weight
gain among psychiatric patients treated with atypical antipsychotic drugs identified a

mean increase of 9.15 lb (4.15 kg) after 10 weeks of olanzapine treatment, second to
clozapine by a mere 0.03 lb (0.01 kg) (Allison & Casey). Randomized, prospective
research investigating longer periods of time found that mean weight gain with
olanzapine was 18.51 lb (8.4 kg) after 3 months and 24.02 lb (10.9 kg) after 1 year
(Perez-Iglesias, Crespo-Facorro, Martinez-Garcia, Ramirez-Bonilla, Alvarez-Jimenez,
Pelayo-Teran, et al., 2008). Weight gain was higher in other prospective research, with a
mean increase of 37.10 lb (16.91 kg) identified after 1 year of olanzapine treatment
(Strassnig et al., 2007).
The FDA defines clinically significant weight gain as a greater than 7% increase
in baseline body weight (Sachs & Guille, 1999), a diagnostic criterion embraced by most
current research. Medication package inserts routinely include information on the percent
of persons who evidence clinically significant weight gain during placebo-controlled
monotherapy drug trials. Results of 13 pooled clinical trials found that 26% of persons
who received olanzapine for 6 to 8 weeks gained more than 7% of their baseline body
weight, with 4% evidencing a 15% or greater increase in weight (Eli Lilly, 2008). After 6
months of olanzapine treatment, 56% of persons gained more than 7% of their baseline
body weight; mean weight gain was 11.9 lb (5.4 kg) at that time. Of the 1,500 individuals
who participated in clinical trials by Eli Lilly, (a) 55% gained between 1.0 to 11.9 lb (0.5
to 5.4 kg), (b) 26% gained between 12.0 to 22.9 lb (5.5 to 10.4 kg), (c) 12% gained
between 23.0 to 33.9 lb (10.5 to 15.4 kg), and (d) 6% gained 34.0 lb (15.5 kg) or more.
Results of recent prospective research found that, by 1 year of olanzapine treatment, 91%
of persons gained more than 7% of their baseline body weight (Strassnig et al., 2007).

Weight gain is believed to contribute to the increased incidence of new-onset DM
type II among psychiatric patients treated with olanzapine (ADA et al., 2004; Eli Lilly,
2008; Lambert, Cunningham, Miller, Dalack, & Hur, 2006). A recent study identified a
significant acute decrease in insulin sensitivity among 14 healthy males who received
olanzapine 10 mg/day for 10 days (Sacher, Mossaheb, Spindelegger, Klein,
Geiss-Granadia, Sauermann, et al., 2008). Administration of higher dosages of
olanzapine has been shown to cause acute hyperglycemia by increasing plasma glucose
by 100% to 140% of basal values without significantly impacting insulin levels (Savory,
Ashton, Miller, Nedza, Spracklin, Hawthorn, et al., 2008).
Pooled results from five placebo-controlled monotherapy drug trials extending 6
to 12 weeks found that fasting glucose levels rose to levels diagnostic of DM type II
(<126 mg/dL) among 2.2% of persons who baseline values were normal (<100 mg/dL)
and 17.4% of persons who baseline values were borderline (>100 mg/dL and <126
mg/dL) (Eli Lilly). Recent epidemiological research identified a comparable 18.2%
incidence for new-onset DM type II among psychiatric outpatients treated with
olanzapine for 3 months (Cohen et al., 2006). Retrospective research of over 1,200
patients in the Department of Veterans Affairs (VA) system found that, after 3 months of
olanzapine treatment, the incidence of new-onset DM type II was 29.9% (Leslie &
Rosenheck, 2005).
Such results underscore the findings of the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) study conducted by the National Institute of Mental
Health on olanzapine, risperidone, quetiapine, and ziprasidone (Lieberman, Stroup,
McEvoy, Swartz, Rosenheck, Perkins, et al., 2005). The randomized, double-blind
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CATIE trial, which cost an estimated $42.6 million, extended 18 months and included
1,400 participants across 57 U.S. cities. Results indicated that olanzapine is superior
among the first-line atypical antipsychotic drugs for the treatment of schizophrenia but
that this increased efficacy is mitigated by severe metabolic effects. Mean weight gain
was 2.0 lb (0.91 kg) per month across the course of drug treatment. Approximately 30%
of persons treated with olanzapine gained 24 lb (10.89 kg) or more after 1 year of
treatment, with this figure rising to 42 lbs (19.05 kg) or greater by 18 months. Several
conclusions were reached regarding olanzapine.
Its apparent superior efficacy is indicated by the lower rate of discontinuation,
greater reduction in psychopathology, longer duration of successful treatment, and
lower rate of hospitalizations for an exacerbation of schizophrenia . . . . [benefits
that must be weighted against the risk for] greater increases in weight and indexes
of glucose and lipid metabolism. (Lieberman et al., p. 1223)
Shortly after the National Institute of Mental Health published the risks of
olanzapine treatment that were identified in the CATIE study (Lieberman et al., 2005),
public and legal controversy ensued. On December 17, 2006, a New York Times article
reported that the newspaper had acquired internal documents and e-mail messages passed
among top executives of Eli Lilly (Berenson). According to the New York Times article,
these documents revealed a decade-long effort by Eli Lilly to minimize knowledge about
the adverse risks of olanzapine, including obesity, hyperglycemia, and diabetes.
Within weeks, the London Times printed excerpts of these documents in which Eli
Lilly identified the risk of drug-induced obesity as a "top threat to sales" since 1998
(Pagnamenta, 2007). Excerpts included an October 2000 report by senior Eli Lilly

research physician Robert Baker who allegedly wrote a top advisory board about being
"quite impressed by the magnitude of weight gain on olanzapine and implications for
glucose". By January 4, 2007, Judge Weinstein of the U.S. District Court had issued a
restraining order to suppress all further printing, posting, and dissemination of Eli Lilly
documents via media, print, and internet ("Legal Battle", 2007). By that time, Eli Lilly
had agreed to pay $1.2 billion to settle 28,000 lawsuits from litigants who claimed they
had gained significant weight and developed new-onset DM type II while being treated
with olanzapine (Berenson, 2007).
Risperidone. Risperidone is currently approved by the FDA for
(a) schizophrenia; (b) mixed and manic states associated with bipolar disorder; and
(c) irritability in children, adolescents, and adults with autistic disorder (Janssen, 2008).
Off-label uses commonly include the treatment of (a) refractory depression without
psychotic features, (b) anxiety disorders, (c) eating disorders, (d) Tourette syndrome, and
(e) disruptive behavior disorders in children (Baldessarini & Tazari; 2006).
Risperidone is classified as an atypical antipsychotic due to its high affinity for
several 5-HT receptor subtypes, including 5-HTia, 2a, and 2c, and regional antagonism of
D 2 receptors (Baldessarini & Tazari, 2006; Miyamoto et al., 2005). Antagonism of
5-HT2A and D2 receptors largely accounts for the therapeutic effects of risperidone, while
antagonism of 5-HT2C receptors is implicated in the liability for weight gain with this
drug. Risperidone also has some potential to induce motor disturbances. However, this
drug evidences a relatively low affinity for D2 receptors in the nigrostriatal region at daily
doses of 6 mg or less, the amount recommended by the FDA, which effectively limits the
risk for EPS (Janssen, 2008).

Weight gain is a common side effect of risperidone treatment. Large sample,
cross-sectional research found that approximately 53% of outpatients with schizophrenia
who received this drug for 4 weeks evidenced some degree of weight gain (Bobes et al.,
2003). The magnitude of weight gain with risperidone is considered intermediate among
the atypical antipsychotics (ADA et al., 2004). Meta-analysis of over 80 studies about
weight gain among psychiatric patients treated with atypical antipsychotic drugs
identified a mean increase of 4.63 lb (2.10 kg) after 10 weeks of risperidone treatment
(Allison & Casey, 2001). Randomized, prospective research investigating longer periods
of time found that mean weight gain with risperidone was 13.00 lb (5.9 kg) after 3
months and 19.62 lb (8.9 kg) after 1 year (Perez-Iglesias et al., 2008). Results are
comparable to the findings from another prospective study that identified a mean increase
of 16.60 lb (7.53 kg) after 1 year of risperidone treatment (Strassnig et al., 2007).
Results of pooled, placebo-controlled clinical trials indicate that 18% of persons
who received risperidone for 6 to 8 weeks gained more than 7% of their baseline body
weight (Janssen, 2008). These figures are comparable to the percent of persons in the
CATIE trials who evidenced clinically significant weight gain after 1 year of risperidone
treatment; approximately 14% of the 300 participants receiving risperidone gained more
than 7% of their baseline body weight after 1 year, with a mean increase of 14.4 lbs (6.53
kg) noted at that time (Lieberman et al., 2005). Recent prospective research found much
higher weight gains, however, with a staggering 51% of individuals having gained more
than 7% of their baseline body weight after 1 year of risperidone treatment (Strassnig
et al., 2007).

Weight gain is believed to increase the risk for new-onset DM type II among
persons who are treated with risperidone (ADA, 2004; Janssen; Lambert et al., 2006).
Recent epidemiological research identified incidence rates of 11.6% for hyperglycemic
events and 16.3% for new-onset DM type II among psychiatric outpatients treated with
olanzapine for 3 months (Cohen et al., 2006). Retrospective research involving almost
1,000 patients from the VA system who were treated with risperidone for 3 months found
a higher incidence rate of 23.3% for new-onset DM type II (Leslie & Rosenheck, 2005).
Quetiapine. Quetiapine is currently approved by the FDA for the treatment of
(a) schizophrenia, (b) acute manic episodes associated with bipolar disorder,
(c) depressive episodes associated with bipolar disorder, and (d) bipolar maintenance
(AstraZeneca, 2008). Off-label uses commonly include the treatment of (a) refractory
depression marked by insomnia, (b) post-traumatic stress disorder, (c) alcoholism,
(d) obsessive-compulsive disorder, (e) Tourette syndrome, and (f) irritability associated
with autism (Baldessarini & Tazari, 2006). Retrospective research also suggests
quetiapine may be an effective treatment for opioid withdrawal by reducing somatic pain,
cravings, anxiety, and insomnia (Pinkofsky, Hahn, Campbell, Rueda, Daley, &
Douaihy, 2005).
Quetiapine is classified as an atypical antipsychotic due to its high affinity for
5-HTi A and several 5-HT2 receptor subtypes as well as regional antagonism of D2
receptors (Baldessarini & Tazari, 2006; Miyamoto et al., 2005). Quetiapine is recognized
as the only antipsychotic drug with a placebo-level incidence for EPS (AstraZeneca,
2008; Kopala, Good, Milliken, Buiteman, Woodley, Rui, et al., 2006; Nasrallah, Brecher,
& Paulsson, 2006; Timdahl, Carlsson, & Stening, 2007). The negligible risk for
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neuromuscular disorders with this agent is attributable to both the reduced occupancy of
and rapid disassociation from D2 receptors in the nigrostriatal region of the brain
(Baldessarini & Tazari; Miyamoto et al.). Quetiapine evidences a strong affinity for Hi
receptors, however, which is thought to account for the notable sedative effects of this
drug. Furthermore, antagonism of Hi and c*2 receptors is believed to impede satiety and
contribute to an increased risk for weight gain with this agent.
Somnolence and sedation, rather than weight gain, are the most common side
effects of quetiapine treatment (AstraZeneca, 2008; Timdahl et al., 2007) and likely
account for recent reports of abuse of this drug (Pierre, Shnayder, Wirshing, & Wirshing,
2004; Pinta & Taylor, 2007; Waters & Joshi, 2007). Anecdotal accounts suggest that as
many as 30% of inmates in correctional settings malinger psychotic symptoms to obtain
and potentially sell quetiapine (Pierre et al.) which has become popularly known as
"quell" (Pierre et al., p. 1718), "Susie Q" (Pinta & Taylor, p. 174), or "baby heroin"
(Waters & Joshi, p. 173). Prisoners reportedly inhale or intravenously inject quetiapine
for optimal anxiolytic and sedative effects. Several clinicians have called for research to
examine the addiction potential of quetiapine, noting that they "have not seen similar
drug-seeking behavior with other second-generation antipsychotics" (Pinta & Taylor, p.
174) which is "reminiscent of the era before the widespread use of atypical antipsychotic
compounds, when a select group of patients would inappropriately seek . . . low-potency
[conventional] antipsychotics" (Pierre et al., p. 1718).
Weight gain is a notable side effect of quetiapine treatment although the
prevalence, magnitude, and course are less severe with this drug than clozapine,
olanzapine, and risperidone (ADA et al., 2004). Randomized, double-blind research of

134 patients with psychosis who received quetiapine for 3 months found a mean weight
increase of 8.12 lb (3.68 kg) (McEvoy, Lieberman, Perkins, Hamer, Hongbin, Lazarus, et
al., 2007). The larger CATIE trial identified a mean weight gain of 6.0 lb (2.72 kg) after 1
year of quetiapine treatment, with this figure rising to just 6.3 lb (2.86 kg) at 18 months
(Lieberman et al., 2005). Results of pooled, placebo-controlled clinical trials are similar,
with a mean increase of 7.02 lb (3.18 kg) identified after 1 year of quetiapine treatment
(Brecher, Leong, Stening, Osterling-Koskinen, & Jones, 2007). Longitudinal analysis of
weight change indicated that the majority of weight gain, more than 60%, occurred
during the first 12 weeks of drug treatment. No clear relationship was identified between
drug dose and weight change, although the magnitude of weight gain was inversely
related to baseline body mass index.
Results of pooled, placebo-controlled clinical trials indicate that 23% of
schizophrenic outpatients who received quetiapine for 3 to 6 weeks gained more than 7%
of their baseline body weight (AstraZeneca, 2008). Randomized, double-blind research
found that 29% evidenced clinically significant weight gain after 3 months of quetiapine
treatment (McEvoy et al., 2007). The CATIE trial furthermore found that 23% of persons
gained more than 7% of their baseline body weight after 18 months of quetiapine
treatment (Lieberman et al., 2005), again suggesting that weight typically stabilizes
within the first few months of drug treatment.
Weight gain is believed to increase the risk for new-onset DM type II among
persons treated with quetiapine (ADA, 2004; AstraZeneca, 2008; Lambert et al., 2006).
In placebo-controlled monotherapy drug trials, fasting glucose levels rose to levels
diagnostic of DM type II (<126 mg/dL) among 3.5% and 4.3% of persons treated with

quetiapine for 12 and 24 weeks, respectively (AstraZeneca). Results are similar to
retrospective research that identified an incidence rate of 3.0% for new-onset DM type II
among 120 patients in the VA system treated with quetiapine for 3 months (Leslie &
Rosenheck, 2005). Longer-term, placebo-controlled drug trials found that fasting glucose
levels <126 mg/dL occurred in 10.7% of persons treated with quetiapine for 30 weeks
(AstraZeneca, 2008). Despite the risk for quetiapine to precipitate diabetes, published
reports remains contradictory about whether or not this drug is associated with a
significantly greater risk for new-onset DM type II relative to conventional antipsychotic
drugs (Lambert et al.; Leslie & Rosenheck).
Ziprasidone. The brand name for ziprasidone, Geodon, has been suggested to
denote the phrase "down to earth" in reference to the goal of this drug (Baldessarini &
Tazari, 2006). Ziprasidone currently is approved by the FDA for the treatment of
(a) schizophrenia, (b) manic and mixed states associated with bipolar disorder, and
(c) acute agitation in persons with schizophrenia (Pfizer, 2008). Limited research also
suggests that ziprasidone may be an effective treatment for aggressive behaviors in
adolescents (Bastiaens, 2008) and behavioral and psychological symptoms of dementia
(Rocha, Hara, Ramos, Kascher, Santos, de Oliveira Lanca, et al., 2006).
Ziprasidone is classified as an atypical antipsychotic due to its high affinity for
5-HTid, 2a, and 2c receptors and regional antagonism of D2 receptors (Baldessarini &
Tazari, 2006; Miyamoto et al., 2005). This drug differs from other atypical antipsychotics
in that it also agonizes some serotonin neurotransmitters, most notably 5-HT)A, and it
also inhibits norepinephrine reuptake with moderate potency (Miyamoto et al., 2005).
Antagonism of 5-HTid, agonism of 5-HTiA, and inhibition of norepinephrine reuptake are

believed to be responsible for the anxiolytic and antidepressant effects of ziprasidone.
This drug also evidences a moderate affinity for Hi and CC2 receptors, however, which
may contribute to sedation and weight gain.
Somnolence is the most common side effect of ziprasidone treatment (Pfizer,
2008). The existing research on weight gain with ziprasidone remains limited, but it
strongly suggests that this drug has a low risk relative to other atypical antipsychotics
(APA et al., 2004; Pfizer). Results of four pooled, placebo-controlled clinical trials
identified a median weight increase of 1.10 lb (0.5 kg) after 4 to 6 weeks of ziprasidone
treatment (Pfizer). Meta-analysis of more than 80 studies on weight gain among
psychiatric patients treated with atypical antipsychotics identified a mean gain of just
0.09 lb (0.04 kg) after 10 weeks of ziprasidone treatment (Allison & Casey, 2001).
The frequently cited CATIE trial identified a mean weight gain of 3.6 lb (1.63 kg)
after 1 year of ziprasidone treatment, with this figure rising to 5.4 lbs (2.24 kg) at 18
months (Lieberman et al., 2005). It should be noted, however, that placebo-controlled
clinical trials extending 52 weeks found that weight change with ziprasidone varied as a
function of baseline BMI category (Pfizer, 2008). These long-term studies identified (a) a
2.87 lb (1.4 kg) mean weight gain among patients with low baseline BMI scores (<23
kg/m2), (b) no mean weight change among those with normal baseline BMI scores (23-27
kg/m2), and (c) a mean weight loss of 2.87 lb (1.3 kg) among patients with high baseline
BMI scores (>27 kg/m2). A recent open-label investigation of weight change among 114
outpatients diagnosed with schizophrenia or schizoaffective disorder who were switched
from olanzapine or risperidone to ziprasidone found significant, sustained improvements
in weight across the course of 52 weeks (Weiden, Newcomer, Loebel, Yang, & Lebovitz,

2008). From baseline to endpoint, mean weight reductions were 21.60 lb (9.8 kg) and
15.21 lb (6.9 kg) for patients who were previously treated with olanzapine and
risperidone, respectively.
Results of pooled, placebo-controlled clinical trials indicate that 6% percent of
persons who received ziprasidone for 6 to 8 weeks gained more than 7% of their baseline
body weight (Pfizer, 2008). The CATIE trial found that just 7% of persons gained more
than 7% of their baseline body weight after 18 months of ziprasidone treatment
(Lieberman et al., 2005) which suggests that weight may stabilize shortly after the
initiation of this drug. Laboratory research on female rats treated with ziprasidone for 28
days indicated clinically significant weight gain on day 28 but failed to identify any
significant change in eating behavior or intra-abdominal fat (Fell, Gibson, McDermott,
Sisodia, Marshall, & Neill, 2005).
The low liability for significant weight gain with ziprasidone is believed to equate
to a negligible risk for new-onset DM type II among persons receiving this drug (ADA et
al., 2004). Although ziprasidone has been associated with new-onset DM type II in at
least one case report (Sanchez-Barranco, 2005), a recent study failed to identify any
significant change in insulin sensitivity among 15 healthy males who received this drug
for 10 days (Sacher et al., 2008). Other research identified significant reductions in mean
weight (-11.24 lb or -5. 1 kg), BMI (-1.6 kg/m2), and serum glucose (-14.0 mg/dL) among
84 outpatients with schizophrenia or schizoaffective disorder who were switched to
ziprasidone for 6 months due to evidencing weight gain, glucose intolerance, diabetes, or
dyslipidemia with other atypical antipsychotic drugs (Montes, Rodriguez, Balbo,
Sopelana, Martin, Soto, et al., 2007). Despite the current lack of research on incidence
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rates for new-onset DM type II with ziprasidone treatment, Pfizer (2008) has noted "few
reports of hyperglycemia or diabetes.... Although fewer patients have been treated with
GEODON [ziprasidone], it is not known if this more limited experience is the sole reason
for the paucity of such reports" (p. 12).
Aripiprazole. The sixth atypical antipsychotic drug to be developed, aripiprazole
currently is approved by the FDA for the treatment of (a) schizophrenia in adults and
adolescents aged 13 to 17 years; (b) acute manic and mixed states associated with bipolar
disorder in adults and pediatric patients aged 10 to 17 years; (c) agitation associated with
schizophrenia and bipolar mania in adults; and (d) major depressive disorder in adults, as
an adjunct (Bristol-Meyers Squibb, 2008). Off-label use frequently includes the treatment
of psychosis associated with abuse of 3,4-methylenedioxymethylamphetamine, more
commonly known ecstasy (Baldessarini & Tazari, 2006). Limited research also suggests
that aripiprazole may be effective in the treatment of (a) delirium (Straker, Shapiro, &
Muskin, 2006); (b) bipolar depression (McElroy, Suppes, Frye, Altshuler, Stanford,
Martens, et al., 2007; Dunn, Stann, Chriki, Filkowski, Ghaemi, 2008); (c) anxiety
(Adson, Kushner, & Fahnhorst, 2005); and (d) aggressive behaviors (Bastiaens, 2008).
Aripiprazole is classified as an atypical antipsychotic due to its high affinity for
5-HT2A receptors and regional antagonism of D2 receptors (Baldessarini & Tazari, 2006;
Miyamoto et al., 2005). Aripiprazole evidences a novel mechanism of action in that its
antipsychotic effects are primarily mediated by functional or ligand-dependent selectivity
for D2 receptors in the mesolimbic and mesocortical brain regions rather than antagonism
or partial agonism at these sites (Urban, Vargas, Zastrow, & Mailman, 2007).

Because aripiprazole is the only ligand-dependent antipsychotic agent approved by the
FDA, it also is known as "the atypical atypical drug" (p. 72). Partial agonism at 5-HTiA
receptors is believed to be responsible for the anxiolytic and antidepressant effects of
aripiprazole (Baldessarini & Tazari; Miyamoto et al.). This drug also evidences a
moderate affinity for H[ and a A receptors which may contribute to sedation and
weight gain.
Although research on weight gain with aripiprazole remains limited, this agent is
generally regarded as having the most favorable side-effect profile of all atypical
antipsychotic drugs (Baldessarini & Tazari, 2006). Placebo-controlled clinical trials
investigating weight gain after 4 to 6 weeks of aripiprazole treatment identified a mean
increase of (a) 1.32 lb (0.60 kg) among persons with mania (Bristol-Myers Squibb,
2008); (b) 1.54 lb (0.71 kg) among those with schizophrenia (Marder, McQuade, Stock,
Kaplita, Marcus, Safferman, et al., 2003); and (c) 2.87 lb (1.30 kg) among those with
major depression (Bristol-Myers Squibb). Small, open-label research identified a similar
increase of 1.76 lb (0.80 kg) among 31 persons with acute bipolar depression treated with
aripiprazole for 8 weeks (McElroy et al., 2007).
Placebo-controlled clinical trials investigating longer periods of time identified
mean weight decreases across all BMI categories after 26 weeks of aripiprazole
treatment; specifically, mean weight loss was (a) -1.10 lb (-0.5 kg) among persons with
low baseline BMI scores (<23 kg/m2) (b) -2.87 lb (-1.3 kg) among those with normal
baseline BMI scores (23-27 kg/m2), and (c) -4.63 lb (-2.1 kg) among those with high
baseline BMI scores (>27 kg/m2) (Bristol-Myers Squibb, 2008). Clinical drug trials
extending 52 weeks found mean weight increases of 5.73 lb (2.6 kg) among persons with

low baseline BMI scores and 3.09 lb (1.4 kg) among those with normal baseline BMI
scores; a mean decrease of -2.65 lb (-1.2 kg) was noted among persons with high baseline
BMI scores. Results of pooled, placebo-controlled clinical trials found that 4% of persons
with depression and 5% of persons with schizophrenia who were treated with aripiprazole
for 6 to 8 weeks gained more than 7% of their baseline body weight (Bristol-Myers
Squibb). No individuals with acute bipolar mania who received drug treatment during
short-term clinical trials evidenced clinically significant weight gain.
Little research has been conducted on the liability new-onset DM type II with
aripiprazole treatment. However, aripiprazole is associated with a more favorable plasma
lipid profile than olanzapine, potentially indicative of a lower metabolic risk with this
drug (McQuade, Stock, Marcus, Jody, Gharbia, Vanveggel, et al., 2004). Furthermore, a
recent open-label pilot study found that patients who evidenced side effects or an
inadequate response with other atypical antipsychotics experienced significant reductions
in fasting glucose and insulin resistance and no longer met criteria for new-onset DM
type II after 3 months of aripiprazole treatment (De Hert et al., 2007). At this time, initial
pharmaceutical investigations suggest more than 100 but less than 1,000 persons are
diagnosed with DM type II after starting aripiprazole (Bristol-Myers Squibb, 2008).
Genetic Variation in Pharmacokinetics and Pharmacodynamics
Little is known about interindividual differences with adverse drug reactions,
particularly with regard to genetic variation in pharmacokinetics and pharmacodynamics
(Buxton, 2006). Pharmacokinetics involves the processes by which the body absorbs,
distributes, metabolizes, and eliminates a drug. Conversely, pharmacodynamics relates to
how a drug affects the biochemistry and physiology of the body. Gender and age are
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known to impact pharmacokinetics and sometimes demonstrate interactive effects on
pharmacodynamics (Buxton; Hilmer, McLachlan, & Le Couteur, 2007; Kaasinen,
Kemppainen, Nagren, Helenius, Kurki, & Rinne, 2002; Schwartz, 2007). For instance,
although the frequency of drug side effects is typically equivalent between genders, the
severity is often greater among females (Buxton; Miller, 2001). Both the frequency and
severity of side effects increase among geriatric adults, as does the likelihood for serious
drug interactions (Buxton; Hilmer et al.; Schwartz, 2007). Furthermore, age-related
changes in neurotransmitters occur at different rates by gender (Schwartz), including the
organic loss of extrastriatal D2 receptors (Kaasinen et al.).
As adults age, gradual changes in pharmacokinetics and pharmacodynamics
increase the interindividual variability of drug dosages necessary to produce a given
effect (Buxton, 2006; Hilmer et al., 2007; Schwartz, 2007). Geriatric adults have a
reduced capacity to metabolize and eliminate many drugs. Such pharmacokinetic
deterioration results from changes in body composition and decreased efficiency of the
organs responsible for drug elimination. For instance, renal functioning among elderly
individuals declines to approximately 50% of that for young adults (Hilmer et al.).
Drug metabolism and hepatic blood flow also decline with age, although the variability in
these changes is great.
The elimination half-lives of drugs frequently increase among geriatric adults due
to larger volume distributions of lipid soluble drugs and reductions in renal and metabolic
clearance (Buxton, 2006; Hilmer et al., 2007; Schwartz, 2007). As a result, elderly
individuals typically require one half to one fourth the drug doses necessary to effectively
treat young adults (Hilmer et al., 2007). However, even if drug dosages are appropriately
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titrated to account for age-related pharmacokinetic changes, increased sensitivity to drugs
may remain due to physiological changes and loss of homeostatic resilience.
Genetic factors such as gender and age have been hypothesized to impact clinical
outcomes and side effects to antipsychotic drug treatment for some time (Murray, 2006;
Nnadi & Malhotra, 2007; Reynolds, Templeman, & Zang, 2005; Usall, Suarez, Haro &
SOHO Study Group, 2007). Some research suggests that females show greater clinical
response and improvement in quality of life with antipsychotic drug treatment (Usall et
al.) but also an increased susceptibility to weight gain, diabetes, and cardiovascular
events (Seeman, 2008). Females also are believed to require lower maintenance doses of
atypical antipsychotics, and doses may need to be titrated among aging women (Seeman,
2006). Both gender and age are recognized to impact the liability for weight gain among
outpatient groups treated with olanzapine (Basson, Kinon, Taylor, Szymanski, Gilmore,
& Tollefson, 2001; Bobes et al., 2003; Hormel, Casey, & Allison, 2002), and some
research suggests that gender may also increase the risk for weight gain with risperidone
(Bobes et al.; Hormel et al.).
Females and geriatric patients treated with olanzapine appear to be more likely to
experience a variety of adverse drug reactions, including increased body weight,
regardless of drug dose (Basson et al., 2001; Bobes et al., 2003; Hormel et al., 2002).
Steady-state plasma concentrations of olanzapine differ by gender and age and may be
one reason that females and elderly adults have a higher prevalence of side effects
(Weiss, Marksteiner, Kemmler, Saria, & Aichhorn, 2006). Weight-corrected olanzapine
plasma concentration/dose ratios average 33.5% higher in females than males,

irrespective of age. Furthermore, weight-corrected concentration/dose ratios increase an
average of 9.4% per decade of life.
Research regarding whether or not gender impacts weight gain with risperidone
remains contradictory. Several studies found that females are at increased risk for weight
gain with risperidone (Bobes et al., 2003; Hormel et al., 2002), although other research
indicates that gender does not significantly affect weight with this agent (Basson et al.,
2002). Initial study of quetiapine suggests that neither gender nor age significantly impact
weight change with this drug (Emsley et al., 2005). No research is yet available on the
susceptibility for weight change by gender and age with aripiprazole and ziprasidone.
Although the prevalence of schizophrenia is approximately equal between the
genders and higher among persons with ID, the majority of clinical trials on atypical
antipsychotic drugs have been conducted with male participants without comorbid ID
(Chaves & Seeman, 2006). Review of 67 randomized, controlled trials of atypical
antipsychotic drug treatment among persons with psychotic disorders found the median
percentage of women in the total sample was 33.3% with some trials including less than
7% (Chaves & Seeman). Chaves and Seeman (2008) noted that "sex differences in
antipsychotic pharmacokinetics and pharmacodynamics that may result in differential
effectiveness and susceptibility to adverse effects cannot be ascertained when the
percentage of women in clinical trials is as low as it is" (p. 19). Furthermore, only one
placebo-controlled study has been conducted to date on atypical antipsychotic drug
treatment among adults with comorbid ID (Hellings et al. 2002). This trial was limited to
an analysis of risperidone and included a sample size of 8 adult participants.

Genetic polymorphisms, or allelic variations independent of gender, have been
linked to interindividual differences in the efficacy and toxicity of many drugs due to
differences in drug-metabolizing enzymes and receptors. In this vein, Santosh and Baird
(1999) noted "an urgent need to understand and establish the pharmacokinetics,
pharmacodynamics, and side-effect profiles of psychotropic medication in this [the ID]
population" (p. 233). A recent analysis of empirical studies, literature reviews, and
policies over the past 25 years furthermore found that, although clinical disorders are
higher among women who have comorbid ID than those who do not, minimal research
has been conducted with this unique treatment group (Taggart, McMillan, & Lawson,
2008). Clearly, additional research designed to be sensitive to how basic pharmacogenetic
factors such as gender, age, and ID may interact with one another and impact adverse
drug reactions is needed at this time.
Weight Gain in Adults with ID Receiving Atypical Antipsychotics
The majority of research on weight gain with atypical antipsychotic drug
treatment has been conducted on outpatient psychiatric groups without comorbid ID.
Review of the literature reveals that five studies have been published to date that
investigate or include an analysis of weight change among adults with ID treated with
atypical antipsychotic drugs. One study has been conducted with olanzapine (Janowsky,
Barnhill, & Davis, 2003), two with risperidone (Cohen, Glazewski, Kahn, & Kahn, 2001;
Hellings, Zarcone, Crandall, Wallace, & Schroeder, 2002), and two with ziprasidone
(Cohen, Fitzgerald, Kahn, & Kahn, 2004; Cohen, Fitzgerald, Okos, Khan, & Khan,
2003). Although one of these studies assessed weight change across children,

adolescents, and adults (Hellings et al.), none included analyses according to gender,
race, level of ID, or increasing age of adults.
Olanzapine. The effectiveness of olanzapine in managing behavioral disorders
among 20 institutionalized adults with ID was evaluated using a retrospective,
open-label, naturalistic design (Janowsky et al., 2003). All participants were receiving
multiple psychotropic drugs at baseline, including conventional antipsychotics, and were
prescribed olanzapine as adjunctive treatment for destructive behaviors, physical
aggression, or SIB. Maladaptive behaviors significantly decreased with add-on
olanzapine treatment, although significant weight gain also was noted. Mean weight
increase was 7.50 lb (3.40 kg) after 6 months of adjunctive olanzapine treatment.
Risperidone. Weight gain with risperidone was investigated in 39 adults with ID
using a retrospective, open-label, naturalistic design (Cohen et al., 2002).
Risperidone was prescribed to manage both clinical and behavioral disorders among
participants, and some also were receiving other psychotropic drugs. Over 2 years, 37 of
the 39 participants evidenced clinically significant weight gain on risperidone. Mean
weight increase was 18.80 lb (8.53 kg) with no association noted between drug dosage
and magnitude of weight gain. The diets of 20 of the 37 participants were calorie
restricted, suggesting that nutritional interventions may be of limited effectiveness in
preventing or ameliorating weight gain among adults with ID treated with risperidone.
In the only placebo-controlled, double-blind, crossover study conducted to date,
weight gain attributable to risperidone was evaluated for five children, six adolescents,
and eight adults diagnosed with ID and autism (Hellings et al., 2002). Significant weight
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gain was noted across all age groups. After 1 year of risperidone treatment, mean weight
increase was 11.88 lb (5.39 kg) for adults, 18.48 lb (8.38 kg) for adolescents, and
18.04 lb (8.18 kg) for children. Rate of weight gain markedly diminished upon tapering
and discontinuation of risperidone treatment.
Ziprasidone. Weight change among 40 adults with ID and maladaptive behaviors
who were switched to ziprasidone after showing a poor clinical response or significant
weight gain with other atypical antipsychotic drugs was investigated in a retrospective,
open-label, naturalistic study (Cohen et al., 2003). Several variables were assessed at
baseline and after 6 months of drug treatment, including weight, triglycerides,
cholesterol, and the frequency of maladaptive behaviors. Ziprasidone was associated with
significant weight loss as well as significant reductions in triglycerides and total
cholesterol, suggesting that this drug carries a reduced risk for metabolic disturbances
relative to other atypical antipsychotic drugs. Participants evidenced a mean weight loss
of 8.10 lb (3.6 kg) after been switched from other atypical agents to ziprasidone.
The frequency of maladaptive behaviors was unchanged or improved for 18 of the 25
participants (72%) for whom data was available.
A replication of this study was conducted with 10 adults diagnosed with both ID
and autism who were switched from other atypical antipsychotic drugs to ziprasidone due
to poor clinical response or significant weight gain with the previous agent (Cohen et al.,
2004). Mean weight loss was slightly greater for this sample than participants only
diagnosed with ID. Eight of the 10 participants lost weight after 6 months of ziprasidone
treatment, with a mean decrease of 13.10 lb (5.94 kg) noted for these individuals. Four of
the five participants for whom data was available evidenced a decrease in total

cholesterol and triglycerides values. The frequency of maladaptive behaviors was
unchanged or improved for seven of the 10 participants.
Goals of the Present Research
Weight gain is a common and potentially severe adverse reaction to atypical
antipsychotic drug treatment and an area worthy of further investigation. The majority of
research conducted to date has involved relatively small sample sizes or included
disproportionately large percentages of males so that the opportunity to investigate
subgroups with adequate statistical power has generally been limited to main medication
groups (for reviews see Chaves & Seeman, 2006; Miller et al., 2005). Furthermore, most
studies assessing the liability for weight gain with atypical antipsychotic drugs have been
restricted to samples with clinical disorders but without comorbid ID (e.g., ADA et al.,
2004; Allison & Casey, 2001; Bobes et al., 2003).
Knowledge of the liability for weight gain among persons with ID clearly remains
tentative due to a paucity of published research. Any attempt to generalize research
findings from clinical samples of persons who function within the average range of
intellectual functioning to persons who have ID carries the risk for error due to variability
in environmental, genetic, pharmacokinetic, and pharmacodynamic factors.
The prevalence and controversy of antipsychotic drug treatment with the ID population
calls for further research be conducted with this unique treatment group. In 2004, the
Consensus Panel called for research that examines adverse metabolic reactions with
atypical antipsychotic drug treatment for specific demographic groups (APA et al., 2004).
An adequate reply has yet to be heard from researchers specializing in the field of ID.
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Small sample size represents a particular concern with the few existing studies
that investigated weight gain among adults with ID treated with atypical antipsychotic
drugs. For the five studies published to date, sample sizes ranged from eight to 40
persons per study (Cohen et al., 2002; Cohen et al., 2003; Cohen et al., 2004; Hellings et
al., 2002; Janowsky et al., 2003). As a result, analysis of the potential interaction between
atypical antipsychotic drug treatment and gender, age, race, or level of ID has not yet
been possible (Aichhorn et al., 2005). Furthermore, direct comparative data are not
available on the liability for weight gain across atypical antipsychotic drugs because each
study was limited to the investigation of one agent. Because antipsychotic drugs continue
to be the most frequently prescribed class of psychotropic medication for persons with
ID, and as there remains a dearth of research on weight gain as an adverse reaction within
this unique and vulnerable treatment group, additional investigation clearly is warranted.
The atypical antipsychotic drugs olanzapine (Eli Lilly, 2008), risperidone
(Janssen, 2008), and quetiapine (AstrasZeneca, 2008) have been approved by the FDA as
first-lines of treatment for schizophrenia and have been determined by the Consensus
Panel to carry either a high or intermediate risk for weight gain (APA et al., 2004).
The goals of the present research are as follows for these drugs: (a) determine if
olanzapine, risperidone, and quetiapine are associated with significant weight gain among
adults with ID after 6 months of drug treatment; (b) determine the average amount of
weight that adults with ID gain after 6 months of drug treatment; (c) determine the
proportion of adults with ID who evidence clinically significant weight gain, defined as a
greater than 7% increase in bodyweight, after 6 months of drug treatment; and

56
(d) identify basic demographic and clinical characteristics of adults with ID who evidence
significant weight gain during drug treatment, including analyses of chlorpromazine
equivalent dose, gender, and level of ID.

Method
Participants
All participants who were involved in this study reside at the largest Intermediate
Care Facility for Individuals with Mental Retardation (ICFMR) in the state of Louisiana.
Criteria for inclusion in the current research included (a) age 18 years or older;
(b) diagnosis of ID; and (c) at least 6 months of continuous treatment with olanzapine,
risperidone, or quetiapine for a comorbid psychiatric or behavioral disorder. A sample of
79 participants met inclusion criteria from a population of 487 individuals.
Demographic characteristics of participants were (a) adults ranging in age from 23 years
to 79 years; (b) 47 males and 32 females; (c) 59 Caucasians and 20 African Americans;
and (d) 14 persons with a diagnosis of mild ID (IQ 50-55 to 70), 21 persons with a
diagnosis of moderate ID (IQ 35-40 to 50-55), 11 persons with a diagnosis of severe ID
(IQ 20-25 to 35-40), and 33 persons with a diagnosis of profound ID (IQ < 20-25).
The participants included in this study receive habilitative treatment for adaptive
skills deficits and behavioral treatment for comorbid psychiatric or behavioral disorders
as mandated by state and federal regulatory guidelines. Licensed, doctoral-level
psychologists complete psychological evaluations and behavior treatment plans on
participants on a yearly or more frequent basis. All evaluations include the administration
of standardized scales to assess (a) level of ID; (b) level of adaptive behavior functioning;
(c) positive and negative social behaviors; (d) nutritional concerns, feeding problems, and
mealtime behaviors; (e) signs of psychopathology; and (f) establishing operations and
maintaining variables for maladaptive behaviors and psychiatric signs. This information
is used to assist in the development of behavior treatment plans that outline positive skills
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training and prevention and management techniques to minimize the frequency, duration,
and intensity of the behavioral or psychiatric disorder.
All participants undergo routine psychiatric evaluations on a quarterly basis or
more frequently when indicated by a change in clinical status. To ensure that drug
treatment is warranted, efficacious, and prescribed at the minimally effective dose, the
following persons attend psychiatric consultations: (a) the individual being treated;
(b) psychiatrist; (c) primary care physician; (c) pharmacist; (d) psychiatric nurse;
(e) licensed, doctoral-level psychologist; (f) master's level associate to a psychologist;
(g) bachelor's level team coordinator; (h) behavior shaping specialist; and (i) residential
support staff.
All participants are weighed monthly by registered nurses who use calibrated
scales and document results. Participants have dietary orders that are individualized
according to caloric and consistency needs, per the recommendations of registered
dieticians and primary care physicians. Dietary orders and weight status are reviewed for
nutritional appropriateness on a monthly basis or more frequently as needed to promote
participants achieving and maintaining optimal health status.
The behavioral, psychiatric, nutritional, and medical status of participants are
monitored and formally reviewed by interdisciplinary teams (IDTs) on a monthly or more
frequent basis to ensure ongoing clinical integrity. IDTs are composed of the following
members: (a) the individual being treated; (b) psychiatrist; (c) primary care physician;
(c) pharmacist; (d) psychiatric nurse; (e) licensed, doctoral-level psychologist;
(f) master's level associate to a psychologist; (g) registered dietician; (h) medical

occupational therapist; (i) physical therapist; (j) speech pathologist; (k) bachelor's level
team coordinator; (1) behavior shaping specialist; and (m) home manager.
Additional habilitative and clinical personnel who may also serve as IDT members
include neurologists, recreation therapists, and employment service representatives.
Multiple review boards are in place to ensure quality control, monitor clinical progress,
and provide treatment recommendations. Review boards include the (a) Clinical Review
Committee, (b) Behavioral Intervention Committee, (c) Human Rights Committee,
(d) Nutritional and Physical Supports Committee, (e) Medical Risks Review Committee,
and (f) Pharmacy and Therapeutics Committee.
Measures
Demographic characteristics. Age, gender, race, and level of ID were gathered
for all participants. Participants were divided into two race groups: (a) Caucasian and
(b) African American. After ascertaining level of ID, participants were also assigned to
one of two ID groups: (a) mild to moderate ID and (b) severe to profound ID.
This grouping was undertaken to further consolidate the sample according to general
level of sensorimotor, communicative, social, and vocational functioning.
Individuals with mild to moderate ID constitute 95% of those with the disorder
(APA, 2002). As a group, they generally acquire social and communication skills during
the preschool to early childhood years and academic skills that range from the second to
sixth grade level. Individuals who function within the mild to moderate range of ID
typically benefit from training in social and vocational skills. They can perform
occupational tasks in the community or at sheltered workshops, which is oftentimes
adequate for minimum self-support.
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By contrast, individuals with severe to profound ID constitute 5% of those with
the disorder (APA, 2002). As a group, they evidence a greater likelihood for
neurological, neuromuscular, cardiovascular, and other medical conditions, and many
have an identified neurological disorder that accounts for their ID. These individuals
acquire little to no communicative speech during the early childhood years and profit
only to a limited extent from instruction in pre-academic subjects such as counting.
Chlorpromazine equivalent dose. Mean 6 month drug dosages of olanzapine,
risperidone, or quetiapine were calculated for all participants. Mean drug doses were then
transformed to chlorpromazine equivalent doses using standard equivalency data in order
to allow for direct dosage comparisons across drugs (Crismon & Dorson, 2006).
Standardization of drug dosages allowed for an absolute comparison of risk for weight
gain during drug treatment.
Body Weight. Body weights were retrieved on all participants for the following
time intervals: (a) 6 months prior to the initiation of atypical antipsychotic drug treatment
(Wl), (b) upon starting the atypical antipsychotic drug (W2), and (c) after 6 consecutive
months of drug treatment (W3). Two weight change scores were calculated for all
participants. The first score (WC1) provided a baseline measure of weight change during
the 6 months prior to the initiation of atypical antipsychotic drug treatment. That is, WC1
served as the pretreatment measure of weight change. WC1 was calculated by subtracting
weight 6 months prior to the initiation of the atypical antipsychotic drug from weight at
the initiation of drug treatment. For example, if a participant weighted 175 lbs (79.38 kg)
6 months prior to the initiation of olanzapine and 180 lb (82.65 kg) upon starting this
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drug, a calculation of 180 - 175 was completed to arrive at a WC1 score of 5 lb (2.27 kg).
The second score (WC2) provided an initial measure of weight change during the first
6 months of atypical antipsychotic drug treatment. That is, WC2 served as an unadjusted
posttreatment measure of weight change. WC2 was calculated by subtracting weight at
the initiation of drug treatment from weight after 6 months of drug receipt. For example,
if the same participant weighed 200 lbs (90.72 kg) after 6 consecutive months of
olanzapine treatment, a calculation of 200 - 180 was completed to arrive at a WC2 score
of 20 lb (9.07 kg).
A third weight change score (WC3) was then calculated for all participants.
This score provided an additional measure of weight change during the first 6 months of
atypical antipsychotic drug treatment, after accounting for individual changes in weight
during the 6 months prior to the initiation of the drug. Thus, WC3 served as an adjusted
posttreatment measure of weight change. WC3 was calculated by subtracting weight
change during the 6 months prior to the initiation of the drug from weight change after 6
months of drug receipt. Continuing the above example, a participant gained 20 lb (9.07
kg) during the first 6 months of olanzapine treatment but already was evidencing an
upward weight change trend of 5 lb (2.27 kg) during the 6 months prior to the receipt of
the drug. Thus, a calculation of 20 lb (9.07 kg) - 5 lb (2.27 kg) was completed to arrive at
a WC3 score of 15 lb (6.80 kg). As noted above, WC3 scores were calculated to provide
an adjusted post-treatment measure for weight change after accounting for individual
changes in weight prior to drug receipt.
The unique value of utilizing the WC1 score is its utility in providing a
pretreatment baseline trend versus a discrete baseline point as the standard for

comparison in assessing weight gain after the initiation of drug treatment. Utilization of
two weight change scores, WC1 and WC2, allowed for a more stringent determination of
the liability for weight gain during atypical antipsychotic drug treatment. That is, WC3
provided for an adjusted dependent measure of weight gain that used each individual as
his or her own control.
Weight increases of more than 7% of body weight also were calculated to
determine the proportion of individuals who evidenced clinically significant weight gain
(a) during the 6 months prior to atypical antipsychotic drug treatment, (b) after 6 months
of drug treatment, and (c) after 6 months of drug treatment with adjustments made for
pretreatment weight change. These calculations were performed because much of the
drug research published to date includes an analysis of the proportion of individuals who
evidenced a greater than 7% increase in baseline body weight during drug treatment.
The FDA also mandates that such proportions be reported in medication package insets
of atypical antipsychotic drugs.
Procedure
All data was accessed from pharmacy databases and medical archival records that
are routinely maintained on participants. Licensed, doctoral-level psychologists had
diagnosed all participants with ID and reviewed the appropriateness of these diagnoses
within the past year. Severity of ID had been determined according to DSM-IV-TR (APA,
2002) diagnostic criteria for mental retardation using standardized intellectual
assessments and informant-based adaptive behavior skills assessments.
Psychiatric and behavioral disorders targeted for atypical antipsychotic drug
treatment had been dually established by licensed, doctoral-level psychologists and
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prescribing psychiatrists. Diagnostic formulations and antipsychotic drug treatments were
evaluated and approved by the Behavior Intervention Committee and Human Rights
Committee of the ICFMR. Informed consent for antipsychotic drug treatment had been
obtained from the curators of participants whose legal status is interdicted adult and from
both the individuals and primary correspondents of persons whose legal status is
competent major. Informed consent grants that all data routinely gathered on the resident
of the ICFMR can be utilized for the advancement of professional research.
The treatment of participant records was in accordance with the "Ethical
Principles of Psychologists and Code of Conduct" (American Psychological Association
[APA], 1992). The ICFMR where the current project was conducted judged the research
procedures to be minimally disruptive to clinical and facility operations. Furthermore, the
project was identified as falling within the minimal to no risk category of the 2005
Department of Health and Human Services' "Code of Federal Regulations", Title
45 - Public Welfare, Part 461 - Protection of Human Rights. The research design and
procedures were reviewed and approved by the Institutional Review Boards of the
ICFMR where the research was conducted (see Appendix A), Louisiana Tech University
(see Appendix B), and the Department of Health and Hospitals for the state of Louisiana
(see Appendix C).
Data Analysis
A retrospective longitudinal design was used to assess changes in body weight
associated with olanzapine, risperidone, and quetiapine treatment. Parameters analyzed
were (a) mean lb (kg) change in body weight after 6 consecutive months of drug
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treatment, (b) percentage change in body weight after 6 consecutive months of drug
treatment, (c) chlorpromazine equivalent dose, (d) gender, and (e) severity of ID.
As noted previously, calculations of change in body weight after 6 months of drug
treatment included adjustments that corrected for baseline body weight trends during the
6 months prior to drug receipt.
Several descriptive analyses were conducted across drug categories and for each
atypical antipsychotic drug. First, descriptive analyses were performed to determine mean
age and the distribution of gender, race, and level of ID. Descriptive analyses were then
performed to determine mean weights and standard deviations (a) 6 months prior to
atypical antipsychotic drug treatment, (b) at the start of drug treatment, and (c) after 6
consecutive months of drug receipt. Descriptive analyses also were performed to
determine means and standard deviations for (a) pretreatment weight change,
(b) posttreatment weight change, and (c) adjusted posttreatment weight change.
Last, the proportion of individuals who evidenced clinically significant weight gain, as
defined by a greater than 7% increase in body weight, was calculated in relation to
(a) pretreatment weight change, (b) posttreatment weight change, and (c) adjusted
posttreatment weight change.
Several statistical tests were conducted. Paired sample /-tests were performed to
determine if there was a significant difference between pretreatment and posttreatment
weight change across drug categories as well as for each atypical antipsychotic drug.
Univariate analysis of variance (ANOVA) was performed to determine if there were
significant differences in adjusted posttreatment weight gain between atypical
antipsychotic drugs. Pearson's product-moment correlation was performed to determine

if there was a significant relationship between adjusted posttreatment weight gain and
chlorpromazine equivalent dose. Last, independent samples /-tests were performed to
determine if there was a significant difference in adjusted posttreatment weight gain
between (a) males and females and (b) persons diagnosed with mild to moderate ID
versus severe to profound ID.

Results
Detailed descriptive data on the demographic and clinical features of participants
are provided in Table 1. The mean age of participants across the sample was 50 years
(range 23 - 79 years) and closely matched the ages for those receiving olanzapine
(M= 51, range 33 - 78), quetiapine (M= 49, range 33 - 66), and risperidone (M= 50,
range 23 - 79). The sample was composed of 47 males (59%) and 32 females (41%).
Males were slightly overrepresented within each of the three drug categories:
(a) Twenty-two males (59%) and 15 females (41%) received olanzapine, (b) 16 males
(62%) and 10 females (38%) received risperidone, and (b) 9 males (56%) and 7 females
(44%) received quetiapine.
The sample largely defined was by Caucasian membership. Fifty-nine Caucasians
(75%) and 20 African Americans (25%) composed the overall sample. Caucasians were
overrepresented within each of the three drug categories: (a) Twenty-eight Caucasians
i

(76%) and 9 African Americans (24%) received olanzapine; (b) 18 Caucasians (69%) and
8 African Americans (31%) received risperidone, and (c) 13 Caucasians (81%) and 3
African Americans (19%) received quetiapine.
The distribution for level of ID, categorized as either mild to moderate or severe
to profound, was well balanced across the overall sample. Thirty-five persons (44%)
functioned in the mild to moderate range of ID, and 44 persons (56%) functioned in the
severe to profound range.
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Table 1
Demographic and Clinical Characteristics of Participants
All

Olanzapine

(TV = 79)

(n = 37)

(n=16)

(n = 26)

50 (23-79)

51 (33-78)

49 (33-66)

50 (23-79)

Male

47 (59%)

22 (59%)

9 (56%)

16 (62%)

Female

32 (41%)

15 (41%)

7 (44%)

10 (38%)

Caucasian

59 (75%)

28 (76%)

13 (81%)

18(69%)

African American

20 (25%)

9 (24%)

3 (19%)

8(31%)

Mild

14(18%)

7 (19%)

1 (6%)

6 (23%)

Moderate

21 (26%)

8 (21%)

6 (38%)

7 (27%)

Severe

11 (14%)

4(11%)

3 (18%)

4(15%)

Profound

33 (42%)

18 (49%)

6 (38%)

9 (35%)

Variable

Age, M (Range)

Quetiapine

Risperidone

Sex, n (%)

Race, n (%)

Level of ID, n (%)

Level of ID within each of drug category was as follows: (a) For olanzapine, 15
participants (40%) functioned in the mild to moderate range, and 22 (60%) functioned in
the severe to profound range; (b) for risperidone, 13 (50%) functioned in the mild to
moderate range, and 13 (50%) functioned in the severe to profound range; and (c) for
quetiapine, 7 participants (44%) functioned in the mild to moderate range, and 9 (56%)
functioned in the severe to profound range.
Detailed descriptive data on the weight trends of participants are presented in
Tables 2, 3, and 4. At the initiation of drug treatment, mean participant weight was
149.92 lb (67.99 kg). Participants gained a mean of 1.67 lb (0.78 kg) during the 6 months
prior to the initiation of drug treatment, with 3.80% of the sample evidencing a greater
than 7% increase on body weight over that time. After 6 consecutive months of atypical
antipsychotic drug treatment, mean participant weight increased from 149.92 lb (67.99
kg) to 162.04 lb (73.49 kg). Participants gained a mean of 12.11 lb (5.49 kg) over that
time, with 41.77% evidencing a greater than 7% increase in body weight and an
additional 12.66% evidencing a greater than 15% increase.
Mean weight increase over the first 6 months of drug treatment was 14.11 lb (6.40
kg) for olanzapine, 11.31 lb (5.13 kg) for risperidone, and 8.81 lb (4.00 kg) for
quetiapine. A greater than 7% increase in body weight was evidenced by 51.35% of those
receiving olanzapine, 42.31% of those receiving risperidone, and 18.75% of those
receiving quetiapine. An additional 16.22% of those receiving olanzapine, 11.54% of
those receiving risperidone, and 6.25% of those receiving quetiapine evidenced a greater
than 15% increase in body weight.
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1

Weights of Participants
Wla

W2 b

W3C

M

147.62(66.96)

148.76(67.46)

162.86(73.86)

SD

32.71 (14.83)

33.34(15.12)

34.51 (15.65)

M

155.25 (70.41)

157.19 (71.29)

166.00(75.28)

SD

35.89 (16.28)

35.22(15.97)

35.65 (16.17)

M

144.85 (65.69)

147.12 (66.72)

158.42 (71.84)

SD

24.82 (11.26)

23.74 (10.77)

25.00 (11.34)

M

148.25 (67.23)

149.92(67.99)

162.04(73.49)

SD

30.88 (14.00)

30.77 (13.95)

31.66(14.36)

Variable

Olanzapine, lb (kg)

Quetiapine, lb (kg)

Risperidone, lb (kg)

All, lb (kg)

a

Weight 6 months prior to the initiation of atypical antipsychotic drug treatment is reported under

column W1. b Weight upon starting atypical antipsychotic drug treatment is reported under
column W2. c Weight after 6 consecutive months of atypical antipsychotic drug treatment is
reported under column W3.
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1

Weight Difference Scores of Participants
Variable

WCl a

WC2 b

WC3 c

Olanzapine, lb (kg)
M

1.14(0.52)

14.11 (6.40)

12.97(5.88)

SD

3.74(1.70)

6.77 (3.07)

7.78 (3.53)

M

1.94(0.89)

8.81 (4.00)

6.87(3.11)

SD

2.46 (1.12)

5.21 (2.36)

6.37 (2.89)

M

2.27(1.03)

11.31 (5.13)

9.04(4.10)

SD

3.31 (1.50)

6.34(2.88)

6.89 (3.12)

M

1.67 (0.78)

12.11 (5.49)

10.44(4.71)

SD

3.38 (1.53)

6.60 (2.99)

7.46 (3.38)

Quetiapine, lb (kg)

Risperidone, lb (kg)

All, lb (kg)

a

Weight change during the 6 months prior to the initiation of atypical antipsychotic drug

treatment is reported under column WC1. b Weight change during the first 6 months of atypical
antipsychotic drug treatment is reported under column WC2. c Weight change during the first 6
months of atypical antipsychotic drug treatment, after adjusting for individual changes in weight
during the 6 months prior to drug treatment, is reported in column WC3.
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1

Percent of Participants Who Evidenced a Clinically Significant Increase in Body Weight
WCl a

WC2 b

>7% weight increase

0.00%

51.35%

43.24%

> 15% weight increase

0.00%

16.22%

12.66%

>7% weight increase

6.25%

18.75%

12.50%

>15% weight increase

0.00%

6.25%

6.25%

>7%) weight increase

7.69%

42.31%

38.46%

> 15%) weight increase

0.00%

11.54%

3.85%

>7% weight increase

3.80%

41.77%

35.44%

>15%) weight increase

0.00%

12.66%

10.13%

Variable

WC3C

Olanzapine

Quetiapine

Risperidone

All

a

Weight change during the 6 months prior to the initiation of atypical antipsychotic drug

treatment is reported under column WC1. b Weight change during the first 6 months of atypical
antipsychotic drug treatment is reported under column WC2. c Weight change during the first 6
months of atypical antipsychotic drug treatment, after adjusting for individual changes in weight
during the 6 months prior to drug treatment, is reported in column WC3.

Paired sample /-tests comparing pretreatment and adjusted posttreatment weight
change were performed across drug categories as well as for each atypical antipsychotic
agent (see Table 5). An adjusted mean weight gain of 8.44 lb (3.82 kg) (SD = 9.09 lb,
4.12 kg) was noted across atypical antipsychotic drugs and found to be significant, t(78)
= 8.26,/? = .000 (two-tailed). For olanzapine, a mean weight gain of 11.14 lb (5.05 kg)
(SD = 9.13 lb, 4.14 kg) was noted and found to be significant t(36) = 7.42, p = .000
(two-tailed). For risperidone, a mean gain of 6.77 lb (3.07 kg) (SD = 8.75 lb, 3.97 kg)
was noted and found to be significant t(25) = 3.94,p = .001 (two-tailed). Lastly, for
quetiapine, a mean gain of 4.94 lb (2.24 kg) (SD = 8.13 lb, 3.69 kg) was noted and also
found to be significant /(15) = 2.43,p = .028 (two-tailed). Findings indicate that
significant weight was associated with 6 months of atypical antipsychotic drug treatment
and with each of the individual agents investigated.
Univariate ANOVA was completed to test for differences in the magnitude of
adjusted posttreatment weight gain across the three atypical antipsychotic drugs
investigated in the study (see Table 6). Analysis yielded a significant difference between
groups, F(2, 76) = 4.68, p = .012. Tukey multiple comparisons indicated that olanzapine
(M= 12.97 lb, 5.88 kg) and quetiapine (M= 6.87 lb, 3.12 kg) was the only pairwise
comparison to reach significance, with a mean weight difference of 6.10 lb (2.77 kg) (SE
= 2.17 lb, 0.98 kg),p = .017. A mean difference of 3.93 lb (1.78 kg) for adjusted
posttreatment weight gain was noted between olanzapine (M = 12.97 lb, 5.88 kg) and
risperidone (M = 9.04 lb, 4.10 kg) but failed to reach significance, p = .092.
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Table 1
Paired Sample t-Tests Comparing Pretreatment and Adjusted

Posttreatment

Weight Change
M

SD

Total, lb (kg)

8.44 (3.82)

9.09(4.12)

Olanzapine, lb (kg)

11.14(5.05)

Quetiapine, lb (kg)
Risperidone, lb (kg)

Pair

t

df

P

8.26*

78

.000

9.13 (4.14)

7.42*

36

.000

4.94 (2.24)

8.13 (3.69)

2 43***

15

.028

6.77 (3.07)

8.75 (3.97)

3.94**

25

.001

(WC3a-WClb)

a

WC3 represents weight change during the first 6 months of atypical antipsychotic drug

treatment, after adjusting for individual changes in weight during the 6 months prior to drug
treatment. b WCl represents weight change during the 6 months prior to the initiation of atypical
antipsychotic drug treatment.
*p < .001, two-tailed. **p < .01, two-tailed. ***p < .05, two-tailed.
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Table 1
Analysis of Variance for Adjusted Posttreatment Weight Change by Atypical
Antipsychotic Drug
F
MS
Source
df

2

245.91

Within Groups

76

52.55

Total

78

Between Groups

4.68

P

.012

Tukey Multiple Comparisons
M difference

SE

olanzapine v. quetiapine, lb (kg)

6.10 (2.77)*

2.17(0.98)

.017

olanzapine v. risperidone, lb (kg)

3.93 (1.78)

1.86 (0.84)

.092

risperidone v. quetiapine, lb (kg)

2.16(0.98)

2.30(1.04)

.617

Comparison

*p < .05.

P

A mean difference of 2.16 lb (0.98 kg) for adjusted posttreatment weight gain was noted
between risperidone (M= 9.04 lb, 4.10 kg) and quetiapine (M = 6.87 lb, 312 kg) also
failed to achieve significance,/? = .617.
Finally, a series of analyses were completed to test the relationship between
adjusted posttreatment weight gain and chlorpromazine equivalent dose, gender, and
level of ID. The relationship between adjusted posttreatment weight gain and
chlorpromazine equivalent dosage was assessed by completing a Pearson's correlation
coefficient. Results did not indicate any significant relationship between weight gain and
drug dosage, r = . 160, p = . 158. An independent samples /-test was performed to
determine if there was a significant difference in adjusted posttreatment weight gain
between males and females (see Table 7). The 1.13. lb (0.51 kg) mean difference in
weight gain noted between males (M= 10.57 lb, 4.79 kg) and females (M= 9.44 lb, 4.28
kg) did not reach significance, /(77) = .66, p = .51 (two-tailed). Last, an independent
samples /-test was performed to determine if there was a significant difference in weight
gain between persons who functioned in the mild to moderate range of ID versus the
severe to profound range of ID (see Table 8). A mean difference of 3.75 lb (1.70 kg) was
noted between persons functioned in the mild to moderate range of ID {M- 14.20 lb,
6.44 kg) versus severe to profound range (M= 10.45 lb, 4.74 kg). Results were found to
be significant, till) = 2.59,p = .011 (two-tailed), and indicate that individuals with lesser
degrees of intellectual impairment have a greater liability for weight gain than those with
greater degrees of impairment.
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Table

1

Independent Samples T-Test Comparing Adjusted, Posttreatment Weight Change by Gender

Males, lb (kg)

M

SD

SE

10.57 (4.79)

7.89(3.58)

1.15 (0.52)

9.44(4.28)

6.86 (3.11)

1.21 (0.55)

(n = 47)
Females, lb (kg)
(n = 32)

t

df

M difference

p

.66

77

1.13 (0.51)

.51
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Table 1
Independent Samples T-test Comparing Adjusted Posttreatment Weight Change by
Level of Intellectual Disability
M

SD

14.20 (6.44)

Mild to Moderate ID, lb (kg)

SE

6.04 (2.74)

1.02 (0.46)

6.62 (3.00)

1.00 (0.45)

(n = 35)
Severe to Profound ID, lb (kg)

10.45 (4.74)

(n = 44)
t

2.59*

*p < .05, two-tailed.

df

M difference

P

77

3.75 (1.70)

.011

Discussion
The current study approached the assessment of weight gain with atypical
antipsychotic drug treatment in a unique manner, even among studies conducted with
typically developed participants. This unique approach to assessing the significance of
weight gain involved comparing weight differences associated with drug treatment to
weight differences observed prior to treatment. In other words, the significance of weight
gain associated with atypical antipsychotic drug treatment was based on comparison with
a baseline weight trend versus a discrete baseline point. Such an approach has clear
methodological implications in that it provides a dependent measure of weight gain that
uses the individual as his or her own control. Such an approach also has potential clinical
implications in that it encourages clinicians and researchers to consider the issue of
weight gain within a broader temporal context.
Even with this more stringent standard for assessing weight gain, results of the
current study demonstrate that significant weight gain is associated with the use of
atypical antipsychotic drugs among persons with ID. Although there have been a small
number of studies demonstrating weight gain with atypical antipsychotic drug treatment
among persons with ID (Cohen et al. 2002; Cohen et al. 2003; Cohen et al. 2004;
Hellings et al. 2002; Janowsky et al. 2003), this was the first study to approach the issue
with any significant methodological complexity. The few previous studies conducted to
date have been limited to assessing weight gain associated with singular atypical
antipsychotic agents, and no research had previously been conducted on the liability for
weight gain with quetiapine among persons with ID. The current study, by contrast,
systematically assessed weight gain across a variety of specific atypical antipsychotic
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drugs, specifically the three most frequently prescribed atypical agents—olanzapine,
risperidone, and quetiapine.
Results of the current study indicate that a substantial proportion of individuals
with ID evidence a significant increase in body weight during treatment with olanzapine,
risperidone, and quetiapine, even after adjusting for individual trends in weight change
prior to drug treatment. Consistent with studies conducted among typically developed
participants, the current research also supports olanzapine as carrying a heightened
liability for weight gain compared to risperidone and quetiapine. Within the typically
developed population, the magnitude of weight gain with olanzapine is recognized to be
the most severe among the atypical antipsychotics considered first line of treatment,
followed by risperidone and then quetiapine (ADA et al. 2004; Allison & Casey, 2001).
By assessing weight change across multiple atypical antipsychotic agents, the current
research is the first of its kind to replicate this finding within the ID population.
The current study also assessed potential risk factors for weight gain among
persons with ID. Analyses of chlorpromazine equivalent drug dosages, gender, and level
of ID were undertaken to evaluate the impact of these variables on liability for weight
gain. Consistent with the literature on atypical antipsychotic drug treatment and weight
gain among typically developed individuals (e.g., see Brecher et al. 2007), the current
study failed to find a significant relationship between drug dosage and magnitude of
weight gain among persons with ID.
Over the past several years, genetic factors such as gender have been
hypothesized to have the potential to impact side effects with antipsychotic drug
treatment (Murray, 2006; Nnadi & Malhotra, 2007; Reynolds et al. 2005; Usall et al.

2007). However, results of empirical research remain mixed. Preliminary research with
typically developed individuals suggests that female gender may increase the liability for
weight gain with olanzapine (Basson et al. 2001; Bobes et al. 2003; Hormel et al. 2002).
Research remains contradictory as to whether gender increases the risk for weight gain
with risperidone (Basson et al. 2002; Bobes et al.; Hormel et al.). Furthermore, initial
study of quetiapine suggests that gender does not significantly impact weight gain with
this drug (Emsley et al. 2005). Results of the current study found that gender did not
significantly impact the liability for weight gain among adults with ID who received
olanzapine, risperidone, and quetiapine.
The current research does, however, implicate the severity of ID as an important
risk factor in the liability for weight gain with atypical antipsychotic drug treatment.
Results of the current study found persons with mild to moderate ID were more likely to
sustain significant weight gain than individuals with severe to profound ID. Given that
individuals with more severe intellectual impairments carry a greater likelihood of
medical challenges, this finding is surprising. Whether severity of ID represents a
pharmacokinetic risk that it impacts the processes by which the body absorbs and
metabolizes drugs or a differential risk in relation to the daily choices of individuals with
ID, such as exercise and dietary habits, remains an area open for further investigation.
All individuals involved in the current research had been prescribed diets that were
individualized according to caloric and medical needs, per the recommendations of
registered dieticians and primary care physicians. However, it may be that individuals
with lesser degrees of intellectual impairment are more able to make choices resulting in
greater caloric intake. That is, these individuals may have more intake options due to

increased independence with mobility, daily routine, and finances. Replicating this
finding and exploring the possible determinants could prove revealing, not just for
persons with ID but also for the individuals who are typically developed.
A number of limitations with the current research must be acknowledged. The
most obvious limitations are those associated with characteristics of the sample. The
current study was limited to the three most frequently prescribed atypical antipsychotic
drugs. Furthermore, sample size for each of the three atypical agents was relatively small
thus calling into question findings related to specific drugs due to questions of sufficient
cell size and power.
The univariate nature of the current study is also a potential concern. Weight gain
as a complication of atypical antipsychotic drug receipt is only a small part of a larger
concern within the scope of health issues such as lipid metabolism, diabetes, and
metabolic syndrome. Future studies would be of greater benefit if they included a broader
range of dependent measures. Future studies could also include a broader consideration
of possible risk factors for the development of problematic weight gain, in addition to
gender and severity of ID. As already noted in the discussion of degree of intellectual
impairment as a risk factor, the detection and exploration of risk factors in those with ID
may prove fruitful not only for persons with ID but also for the general population.
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Appendix A
Human Rights Committee Approval from Pinecest Supports & Services Center
MEMORANDUM
TO: John Newsom, DHH Institutional Review Board
FROM: Amanda Pittman, Chair, Human Rights Committee, Pinecrest Supports &
Services Center
DATE: April 17, 2009
Weight Gain among Adults with Intellectual Disabilities Receiving Atypical
Antipsychotics

I have reviewed the above-entitled research proposal. The research procedures appear to
be minimally disruptive to clinical and facility operations. I agree to provide the
necessary support requested in the application and hereby designate myself as the staff
member responsible for monitoring these research activities.
I understand that any modifications to the research proposal must be approved by the
DHH IRB prior to implementation. I agree to suspend research activities and to report to
the DHH IRB any unauthorized research modifications or instances in which client rights
appear to be violated.
I understand that the researcher is not authorized to begin research activities at this
facility until written authorization from the Secretary or designee is received.
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Appendix A
Institutional Review Board Approval from Louisiana Tech University
MEMORANDUM
TO:

Dr. Tony Young

FROM:

Barbara Talbot, University Research

SUBJECT:

HUMAN USE COMMITTEE REVIEW

DATE:

June 24, 2009

In order to facilitate your project, an EXPEDITED REVIEW has been done for your proposed
study entitled:

"Weight Gain among Adults with Intellectual Disabilities
Receiving Atypical Antipsychotics"
# HUC 654*
The proposed study's revised procedures were found to provide reasonable and adequate
safeguards against possible risks involving human subjects. The information to be collected may
be personal in nature or implication. Therefore, diligent care needs to be taken to protect the
privacy of the participants and to assure that the data are kept confidential. Informed consent is a
critical part of the research process. The subjects must be informed that their participation is
voluntary. It is important that consent materials be presented in a language understandable to
every participant. If you have participants in your study whose first language is not English, be
sure that informed consent materials are adequately explained or translated. Since your reviewed
project appears to do no damage to the participants, the Human Use Committee grants approval
of the involvement of human subjects as outlined.
Projects should be renewed annually. This approval was finalized on June 24, 2009 and this
project will need to receive a continuation review by the IRB if the project, including data
analysis, continues beyond June 24, 2010. Any discrepancies in procedure or changes that have
been made including approved changes should be noted in the review application. Projects
involving NIH funds require annual education training to be documented. For more information
regarding this, contact the Office of University Research.
You are requested to maintain written records of your procedures, data collected, and subjects
involved. These records will need to be available upon request during the conduct of the study
and retained by the university for three years after the conclusion of the study. If changes occur
in recruiting of subjects, informed consent process or in your research protocol, or if
unanticipated problems should arise it is the Researchers responsibility to notify the Office of
Research or IRB in writing. The project should be discontinued until modifications can be
reviewed and approved.
If you have any questions, please contact Dr. Mary Livingston at 257-4315.
*NOTE: Approval contingent on DHH IRB final written approval in our file before data
collection can begin.
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A

Institutional Review Board Approval from the Department of Health and Hospitals

State of Louisiana
Department of Health and Hospitals
July 21, 2009

Sherri Transier, M.S.
1927 White street
Alexandria, LA 71301
Re: Weight Disturbances in Adults with Intellectual Disabilities Receiving Atypical
Antipsychotics
Dear Ms Transier:
Thank you for submitting the above protocol for DHH IRB review. Your protocol has been
reviewed under Expedited Review procedures and is approved for start-up at your convenience. It
is noted that the study has received approval of the Louisiana Tech Institutional Review Board.
I am requesting that any emergent problems, serious adverse reactions, or changes to protocol that
may affect the status of the investigation be reported to this office and that no such changes be
instituted prior to DHH IRB review, except where necessary in order to eliminate immediate
hazards. The investigator also agrees to periodic review of this project by the DHH IRB at
intervals appropriate to the degree of risk to assure that it is being conducted in compliance with
the DHH IRB's understanding and recommendations.
If we can be of any further assistance please feel free to call.
Sincerely,
John D. Newsom, II, M.A., CPM
Chair, DHH IRB

IRB #: 00003451
FWA #: 00004713
c:

Julia Kenny
Kathy Kliebert
Amanda Pittman.
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